[1]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5); American Psychiatric Association: Arlington, VA, 2013.
[2]
Rasmussen, S.A.; Eisen, J.L. The epidemiology and differential diagnosis of obsessive compulsive disorder. J. Clin. Psychiatry, 1994, 55(Suppl.), 5-10. [PMID: 7961532].
[3]
Ruscio, A.M.; Stein, D.J.; Chiu, W.T.; Kessler, R.C. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol. Psychiatry, 2010, 15(1), 53-63. [http://dx.doi.org/10.1038/mp.2008.94]. [PMID: 18725912].
[4]
Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R.; Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry, 2005, 62(6), 593-602. [http://dx.doi. org/10.1001/archpsyc.62.6.593]. [PMID: 15939837].
[5]
Geller, D.A.; Biederman, J.; Jones, J.; Shapiro, S.; Schwartz, S.; Park, K.S. Obsessive-compulsive disorder in children and adolescents: a review. Harv. Rev. Psychiatry, 1998, 5(5), 260-273. [http://dx.doi.org/10.3109/10673229809000309]. [PMID: 9493948].
[6]
Geller, D.A. Obsessive-compulsive and spectrum disorders in children and adolescents. Psychiatr. Clin. North Am., 2006, 29(2), 353-370. [http://dx.doi.org/10.1016/j.psc.2006.02.012]. [PMID: 16650713].
[7]
Heyman, I.; Fombonne, E.; Simmons, H.; Ford, T.; Meltzer, H.; Goodman, R. Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental health. Int. Rev. Psychiatry, 2003, 15(1-2), 178-184. [http://dx.doi.org/10.1080/0954026021 000046146]. [PMID: 12745330].
[8]
Anholt, G.E.; Aderka, I.M.; van Balkom, A.J.; Smit, J.H.; Schruers, K.; van der Wee, N.J.; Eikelenboom, M.; De Luca, V.; van Oppen, P. Age of onset in obsessive-compulsive disorder: admixture analysis with a large sample. Psychol. Med., 2014, 44(1), 185-194. [http:// dx.doi.org/10.1017/S0033291713000470]. [PMID: 23517651].
[9]
Mataix-Cols, D.; Marks, I.M.; Greist, J.H.; Kobak, K.A.; Baer, L. Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial. Psychother. Psychosom., 2002, 71(5), 255-262. [http:// dx.doi.org/10.1159/000064812]. [PMID: 12207105].
[10]
Stewart, S.E.; Geller, D.A.; Jenike, M.; Pauls, D.; Shaw, D.; Mullin, B.; Faraone, S.V. Long-term outcome of pediatric obsessive-compulsive disorder: a meta-analysis and qualitative review of the literature. Acta Psychiatr. Scand., 2004, 110(1), 4-13. [http://dx. doi.org/10.1111/j.1600-0447.2004.00302.x]. [PMID: 15180774].
[11]
World Health Organization (WHO). The Global Burden of Disease: 2004 Update; World Health Organization: Geneva, Switzerland, 2008.
[12]
Hirschtritt, M.E.; Bloch, M.H.; Mathews, C.A. Obsessive-compulsive disorder: Advances in diagnosis and treatment. JAMA, 2017, 317(13), 1358-1367. [http://dx.doi.org/10.1001/jama.2017.2200]. [PMID: 28384832].
[13]
Leon, A.C.; Olfson, M.; Broadhead, W.E.; Barrett, J.E.; Blacklow, R.S.; Keller, M.B.; Higgins, E.S.; Weissman, M.M. Prevalence of mental disorders in primary care. Implications for screening. Arch. Fam. Med., 1995, 4(10), 857-861. [http://dx.doi.org/10.1001/ archfami.4.10.857]. [PMID: 7551133].
[14]
Veldhuis, J.; Dieleman, J.P.; Wohlfarth, T.; Storosum, J.G.; van Den Brink, W.; Sturkenboom, M.C.; Denys, D. Incidence and prevalence of “diagnosed OCD” in a primary care, treatment seeking, population. Int. J. Psychiatry Clin. Pract., 2012, 16(2), 85-92. [http:// dx.doi.org/10.3109/13651501.2011.617454]. [PMID: 22122660].
[15]
Glazier, K.; Calixte, R.M.; Rothschild, R.; Pinto, A. High rates of OCD symptom misidentification by mental health professionals. Ann. Clin. Psychiatry, 2013, 25(3), 201-209. [PMID: 23926575].
[16]
Dell’Osso, B.; Camuri, G.; Benatti, B.; Buoli, M.; Altamura, A.C. Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder. Early Interv. Psychiatry, 2013, 7(4), 374-380. [http://dx.doi.org/10.1111/eip.12016]. [PMID: 23347385].
[17]
Altamura, A.C.; Buoli, M.; Albano, A.; Dell’Osso, B. Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study. Int. Clin. Psychopharmacol., 2010, 25(3), 172-179. [http://dx.doi.org/10. 1097/YIC.0b013e3283384c74]. [PMID: 20305566].
[18]
Torres, A.R.; Prince, M.J.; Bebbington, P.E.; Bhugra, D.K.; Brugha, T.S.; Farrell, M.; Jenkins, R.; Lewis, G.; Meltzer, H.; Singleton, N. Treatment seeking by individuals with obsessive-compulsive disorder from the british psychiatric morbidity survey of 2000. Psychiatr. Serv., 2007, 58(7), 977-982. [http://dx.doi.org/ 10.1176/ps.2007.58.7.977]. [PMID: 17602015].
[19]
Torres, A.R.; Prince, M.J.; Bebbington, P.E.; Bhugra, D.; Brugha, T.S.; Farrell, M.; Jenkins, R.; Lewis, G.; Meltzer, H.; Singleton, N. Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000. Am. J. Psychiatry, 2006, 163(11), 1978-1985. [http://dx. doi.org/10.1176/ajp.2006.163.11.1978]. [PMID: 17074950].
[20]
Skapinakis, P.; Caldwell, D.M.; Hollingworth, W.; Bryden, P.; Fineberg, N.A.; Salkovskis, P.; Welton, N.J.; Baxter, H.; Kessler, D.; Churchill, R.; Lewis, G. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry, 2016, 3(8), 730-739. [http://dx.doi.org/10.1016/S2215-0366(16)30069-4]. [PMID: 27318812].
[21]
Cottraux, J.; Bouvard, M.A.; Milliery, M. Combining Pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder. Cogn. Behav. Ther., 2005, 34(3), 185-192. [http://dx.doi.org/10.1080/16506070510043750]. [PMID: 16201063].
[22]
Pallanti, S.; Quercioli, L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(3), 400-412. [http://dx.doi.org/10.1016/j.pnpbp.2005. 11.028]. [PMID: 16503369].
[23]
Kaplan, A.; Hollander, E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr. Serv., 2003, 54(8), 1111-1118. [http://dx.doi.org/10.1176/appi.ps.54.8.1111]. [PMID: 12883138].
[24]
Simpson, H.B.; Liebowitz, M.R.; Foa, E.B.; Kozak, M.J.; Schmidt, A.B.; Rowan, V.; Petkova, E.; Kjernisted, K.; Huppert, J.D.; Franklin, M.E.; Davies, S.O.; Campeas, R. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress. Anxiety, 2004, 19(4), 225-233. [http://dx.doi.org/10. 1002/da.20003]. [PMID: 15274171].
[25]
Stein, D.J.; Andersen, E.W.; Tonnoir, B.; Fineberg, N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr. Med. Res. Opin., 2007, 23(4), 701-711. [http://dx.doi.org/10.1185/ 030079907X178838]. [PMID: 17407626].
[26]
Dell’Osso, B.; Nestadt, G.; Allen, A.; Hollander, E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review. J. Clin. Psychiatry, 2006, 67(4), 600-610. [http://dx.doi.org/10.4088/JCP.v67n0411]. [PMID: 16669725].
[27]
Soomro, G.M.; Altman, D.; Rajagopal, S.; Oakley-Browne, M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst. Rev., 2008, (1)CD001765 [PMID: 18253995].
[28]
Issari, Y.; Jakubovski, E.; Bartley, C.A.; Pittenger, C.; Bloch, M.H. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. J. Clin. Psychiatry, 2016, 77(5), e605-e611. [http://dx.doi.org/10.4088/JCP. 14r09758]. [PMID: 27249090].
[29]
Fineberg, N.A.; Pampaloni, I.; Pallanti, S.; Ipser, J.; Stein, D.J. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 2007, 22(6), 313-322. [http://dx.doi.org/10.1097/YIC.0b013e32825 ea312]. [PMID: 17917549].
[30]
Fineberg, N.A.; Tonnoir, B.; Lemming, O.; Stein, D.J. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur. Neuropsychopharmacol., 2007, 17(6-7), 430-439. [http://dx.doi.org/ 10.1016/j.euroneuro.2006.11.005]. [PMID: 17240120].
[31]
Landeros-Weisenberger, A.; Bloch, M.H.; Kelmendi, B.; Wegner, R.; Nudel, J.; Dombrowski, P.; Pittenger, C.; Krystal, J.H.; Goodman, W.K.; Leckman, J.F.; Coric, V. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder. J. Affect. Disord., 2010, 121(1-2), 175-179. [http://dx.doi.org/10. 1016/j.jad.2009.06.010]. [PMID: 19577308].
[32]
Saxena, S.; Brody, A.L.; Ho, M.L.; Zohrabi, N.; Maidment, K.M.; Baxter, L.R., Jr Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am. J. Psychiatry, 2003, 160(3), 522-532. [http://dx.doi. org/10.1176/appi.ajp.160.3.522]. [PMID: 12611834].
[33]
Mataix-Cols, D.; Rauch, S.L.; Manzo, P.A.; Jenike, M.A.; Baer, L. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 1999, 156(9), 1409-1416. [PMID: 10484953].
[34]
Erzegovesi, S.; Cavallini, M.C.; Cavedini, P.; Diaferia, G.; Locatelli, M.; Bellodi, L. Clinical predictors of drug response in obsessive-compulsive disorder. J. Clin. Psychopharmacol., 2001, 21(5), 488-492. [http://dx.doi.org/10.1097/00004714-200110000-00006]. [PMID: 11593074].
[35]
Tükel, R.; Bozkurt, O.; Polat, A.; Genç, A.; Atli, H. Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Psychiatry Clin. Neurosci., 2006, 60(4), 404-409. [PMID: 16884439].
[36]
Hollander, E.; Allen, A.; Steiner, M.; Wheadon, D.E.; Oakes, R.; Burnham, D.B. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J. Clin. Psychiatry, 2003, 64(9), 1113-1121. [http://dx.doi.org/10.4088/ JCP.v64n0919]. [PMID: 14628989].
[37]
Stein, M.B.; Liebowitz, M.R.; Lydiard, R.B.; Pitts, C.D.; Bushnell, W.; Gergel, I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA, 1998, 280(8), 708-713. [http://dx.doi.org/10.1001/jama.280.8.708]. [PMID: 9728642].
[38]
Goljevscek, S.; Carvalho, L.A. Current management of obsessive and phobic states. Neuropsychiatr. Dis. Treat., 2011, 7, 599-610. [http://dx.doi.org/10.2147/NDT.S17032]. [PMID: 22003299].
[39]
Zohar, J.; Judge, R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br. J. Psychiatry, 1996, 169(4), 468-474. [http://dx.doi.org/10.1192/bjp.169.4.468]. [PMID: 8894198].
[40]
Li, J.; Xiang, H.; Du, H. Clinical controlled study of paroxetine and clomipramine in treatment of obsessive- compulsive disorder. Chin. J. Psychiatry, 1998, 31(4), 215-217.
[41]
Geller, D.A.; Wagner, K.D.; Emslie, G.; Murphy, T.; Carpenter, D.J.; Wetherhold, E.; Perera, P.; Machin, A.; Gardiner, C. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry, 2004, 43(11), 1387-1396. [http://dx.doi.org/10.1097/01.chi.0000138356. 29099.f1]. [PMID: 15502598].
[42]
Kamijima, K.; Murasaki, M.; Asai, M.; Higuchi, T.; Nakajima, T.; Taga, C.; Matsunaga, H. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin. Neurosci., 2004, 58(4), 427-433. [http://dx.doi.org/10.1111/j.1440-1819.2004.01278.x]. [PMID: 15298657].
[43]
Ushijima, S.; Kamijima, K.; Asai, M.; Murasaki, M.; Nakajima, T.; Kudo, Y.; Tashiro, N.; Kurihara, M.; Miura, S. Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor in the treatment of obsessive- compulsive disorder: A double blind placebo controlled trial. Jpn. J. Neuropsychoph., 1997, 19(6), 603-623.
[44]
Mallya, G.K.; White, K.; Waternaux, C.; Quay, S. Short- and long-term treatment with obsessive-compulsive disorder with fluvoxamine. Ann. Clin. Psychiatry, 1992, 4, 77-80. [http://dx.doi.org/10. 3109/10401239209150443].
[45]
Nakajima, T.; Kudo, Y.; Yamashita, I.; Asai, M.; Kamijima, K.; Murasaki, M.; Yamaguchi, N.; Saito, M.; Yamawaki, S.; Nishizono, M.; Hishikawa, Y.; Machiyama, Y.; Yamauchi, T.; Moriya, N.; Toru, M.; Hirose, T.; Kojima, T.; Shimizu, M.; Tamura, A.; Endo, S.; Suzuki, J.; Takemasa, K.; Uno, M.; Hasegawa, K.; Kariya, T. Clinical usefulness of Fluvoxamine Maleate (SME3110), a selective serotonin reuptake inhibitor, in the treatment of obsessive compulsive disorder: A double blind, placebo-controlled study investigating the therapeutic dose range and the efficacy of SME3110. J. Clin. Ther. Med., 1996, 12(3), 409-437. [Rinshou Iyaku].
[46]
Nakatani, E.; Nakagawa, A.; Nakao, T.; Yoshizato, C.; Nabeyama, M.; Kudo, A.; Isomura, K.; Kato, N.; Yoshioka, K.; Kawamoto, M. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine. Psychother. Psychosom., 2005, 74(5), 269-276. [http://dx. doi.org/10.1159/000086317]. [PMID: 16088264].
[47]
Hollander, E.; Koran, L.M.; Goodman, W.K.; Greist, J.H.; Ninan, P.T.; Yang, H.; Li, D.; Barbato, L.M. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J. Clin. Psychiatry, 2003, 64(6), 640-647. [http://dx.doi.org/10.4088/ JCP.v64n0604]. [PMID: 12823077].
[48]
Goodman, W.K.; Kozak, M.J.; Liebowitz, M.; White, K.L. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int. Clin. Psychopharmacol., 1996, 11(1), 21-29. [http://dx.doi.org/10.1097/ 00004850-199603000-00003]. [PMID: 8732310].
[49]
Riddle, M.A.; Reeve, E.A.; Yaryura-Tobias, J.A.; Yang, H.M.; Claghorn, J.L.; Gaffney, G.; Greist, J.H.; Holland, D.; McConville, B.J.; Pigott, T.; Walkup, J.T. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J. Am. Acad. Child Adolesc. Psychiatry, 2001, 40(2), 222-229. [http://dx.doi.org/10.1097/00004583-200102000-00017]. [PMID: 11211371].
[50]
O’Connor, K.P.; Aardema, F.; Robillard, S.; Guay, S.; Pélissier, M.C.; Todorov, C.; Borgeat, F.; Leblanc, V.; Grenier, S.; Doucet, P. Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder. Acta Psychiatr. Scand., 2006, 113(5), 408-419. [http://dx.doi.org/10.1111/j.1600-0447.2006.00767. x]. [PMID: 16603032].
[51]
Goodman, W.K.; Price, L.H.; Rasmussen, S.A.; Delgado, P.L.; Heninger, G.R.; Charney, D.S. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch. Gen. Psychiatry, 1989, 46(1), 36-44. [http://dx.doi. org/10.1001/archpsyc.1989.01810010038006]. [PMID: 2491940].
[52]
Jenike, M.A.; Hyman, S.; Baer, L.; Holland, A.; Minichiello, W.E.; Buttolph, L.; Summergrad, P.; Seymour, R.; Ricciardi, J. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am. J. Psychiatry, 1990, 147(9), 1209-1215. [http://dx.doi.org/10.1176/ajp.147.9.1209]. [PMID: 2143637].
[53]
Stein, M.B.; Fyer, A.J.; Davidson, J.R.; Pollack, M.H.; Wiita, B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am. J. Psychiatry, 1999, 156(5), 756-760. [PMID: 10327910].
[54]
Ravizza, L.; Barzega, G.; Bellino, S.; Bogetto, F.; Maina, G. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol. Bull., 1996, 32(1), 167-173. [PMID: 8927668].
[55]
Stein, D.J.; Andersen, E.W.; Overo, K.F. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Rev. Bras. Psiquiatr., 2007, 29(4), 303-307. [http://dx.doi.org/10.1590/S1516-44462007000400003]. [PMID: 18200396].
[56]
Montgomery, S.A.; Kasper, S.; Stein, D.J.; Bang Hedegaard, K.; Lemming, O.M. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 2001, 16(2), 75-86. [http://dx.doi.org/10.1097/00004850-200103000-00002]. [PMID: 11236072].
[57]
Atmaca, M.; Kuloglu, M.; Tezcan, E.; Unal, A. Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum. Psychopharmacol., 2002, 17(8), 401-405. [http://dx.doi.org/10.1002/hup.436]. [PMID: 12457375].
[58]
Marazziti, D.; Golia, F.; Consoli, G.; Presta, S.; Pfanner, C.; Carlini, M.; Mungai, F.; Catena Dell’osso, M. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr., 2008, 13(11), 971-976. [http:// dx.doi.org/10.1017/S1092852900014024]. [PMID: 19037176].
[59]
Sánchez, C.; Bergqvist, P.B.; Brennum, L.T.; Gupta, S.; Hogg, S.; Larsen, A.; Wiborg, O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl.), 2003, 167(4), 353-362. [http://dx.doi.org/10.1007/s00213-002-1364-z]. [PMID: 12719960].
[60]
von Moltke, L.L.; Greenblatt, D.J.; Giancarlo, G.M.; Granda, B.W.; Harmatz, J.S.; Shader, R.I. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab. Dispos., 2001, 29(8), 1102-1109. [PMID: 11454728].
[61]
Burke, W.J.; Kratochvil, C.J. Stereoisomers in Psychiatry: The Case of Escitalopram. Prim. Care Companion J. Clin. Psychiatry, 2002, 4(1), 20-24. [http://dx.doi.org/10.4088/PCC.v04n0107]. [PMID: 15014731].
[62]
Lader, M.; Stender, K.; Bürger, V.; Nil, R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety, 2004, 19(4), 241-248. [http://dx.doi. org/10.1002/da.20014]. [PMID: 15274173].
[63]
Tollefson, G.D.; Rampey, A.H., Jr; Potvin, J.H.; Jenike, M.A.; Rush, A.J. kominguez, R.A.; Koran, L.M.; Shear, M.K.; Goodman, W.; Genduso, L.A. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1994, 51(7), 559-567. [http://dx.doi.org/10.1001/ archpsyc.1994.03950070051010]. [PMID: 8031229].
[64]
Romano, S.; Goodman, W.; Tamura, R.; Gonzales, J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J. Clin. Psychopharmacol., 2001, 21(1), 46-52. [http://dx.doi.org/10.1097/00004714-200102000-00009]. [PMID: 11199947].
[65]
Phillips, K.A.; Rasmussen, S.A. Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study. Psychosomatics, 2004, 45(5), 438-444. [http://dx.doi.org/10.1176/appi.psy.45.5.438]. [PMID: 15345790].
[66]
Davidson, J.R.; Foa, E.B.; Huppert, J.D.; Keefe, F.J.; Franklin, M.E.; Compton, J.S.; Zhao, N.; Connor, K.M.; Lynch, T.R.; Gadde, K.M. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch. Gen. Psychiatry, 2004, 61(10), 1005-1013. [http://dx.doi.org/10.1001/archpsyc.61.10.1005]. [PMID: 15466674].
[67]
Riddle, M.A.; Scahill, L.; King, R.A.; Hardin, M.T.; Anderson, G.M.; Ort, S.I.; Smith, J.C.; Leckman, J.F.; Cohen, D.J. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J. Am. Acad. Child Adolesc. Psychiatry, 1992, 31(6), 1062-1069. [http://dx.doi.org/10. 1097/00004583-199211000-00011]. [PMID: 1429406].
[68]
Montgomery, S.A.; McIntyre, A.; Osterheider, M.; Sarteschi, P.; Zitterl, W.; Zohar, J.; Birkett, M.; Wood, A.J. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur. Neuropsychopharmacol., 1993, 3(2), 143-152. [http://dx.doi.org/10.1016/0924-977X(93)90266-O]. [PMID: 8364350].
[69]
Geller, D.A.; Hoog, S.L.; Heiligenstein, J.H.; Ricardi, R.K.; Tamura, R.; Kluszynski, S.; Jacobson, J.G. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J. Am. Acad. Child Adolesc. Psychiatry, 2001, 40(7), 773-779. [http://dx.doi.org/10.1097/00004583-200107000-00011]. [PMID: 11437015].
[70]
Tollefson, G.D.; Birkett, M.; Koran, L.; Genduso, L. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J. Clin. Psychiatry, 1994, 55(Suppl.), 69-76. [PMID: 7961535].
[71]
Jenike, M.A.; Baer, L.; Minichiello, W.E.; Rauch, S.L.; Buttolph, M.L. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am. J. Psychiatry, 1997, 154(9), 1261-1264. [http://dx.doi.org/10.1176/ajp.154.9.1261]. [PMID: 9286186].
[72]
Greist, J.; Chouinard, G.; DuBoff, E.; Halaris, A.; Kim, S.W.; Koran, L.; Liebowitz, M.; Lydiard, R.B.; Rasmussen, S.; White, K.; Sikes, C. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1995, 52(4), 289-295. [http://dx.doi. org/10.1001/archpsyc.1995.03950160039008]. [PMID: 7702445].
[73]
Liebowitz, M.R.; DeMartinis, N.A.; Weihs, K.; Londborg, P.D.; Smith, W.T.; Chung, H.; Fayyad, R.; Clary, C.M. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J. Clin. Psychiatry, 2003, 64(7), 785-792. [http://dx.doi.org/10.4088/JCP.v64n0708]. [PMID: 12934979].
[74]
Van Ameringen, M.A.; Lane, R.M.; Walker, J.R.; Bowen, R.C.; Chokka, P.R.; Goldner, E.M.; Johnston, D.G.; Lavallee, Y.J.; Nandy, S.; Pecknold, J.C.; Hadrava, V.; Swinson, R.P. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am. J. Psychiatry, 2001, 158(2), 275-281. [http://dx.doi.org/10.1176/appi.ajp.158.2.275]. [PMID: 11156811].
[75]
Kronig, M.H.; Apter, J.; Asnis, G.; Bystritsky, A.; Curtis, G.; Ferguson, J.; Landbloom, R.; Munjack, D.; Riesenberg, R.; Robinson, D.; Roy-Byrne, P.; Phillips, K.; Du Pont, I.J. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J. Clin. Psychopharmacol., 1999, 19(2), 172-176. [http://dx.doi.org/10.1097/00004714-199904000-00013]. [PMID: 10211919].
[76]
Koran, L.M.; Hackett, E.; Rubin, A.; Wolkow, R.; Robinson, D. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 2002, 159(1), 88-95. [http://dx.doi.org/10.1176/appi.ajp.159.1.88]. [PMID: 11772695].
[77]
Chouinard, G.; Goodman, W.; Greist, J.; Jenike, M.; Rasmussen, S.; White, K.; Hackett, E.; Gaffney, M.; Bick, P.A. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol. Bull., 1990, 26(3), 279-284. [PMID: 2274626].
[78]
Ninan, P.T.; Koran, L.M.; Kiev, A.; Davidson, J.R.; Rasmussen, S.A.; Zajecka, J.M.; Robinson, D.G.; Crits-Christoph, P.; Mandel, F.S.; Austin, C. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J. Clin. Psychiatry, 2006, 67(1), 15-22. [http:// dx.doi.org/10.4088/JCP.v67n0103]. [PMID: 16426083].
[79]
Abramowitz, J.S. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J. Consult. Clin. Psychol., 1997, 65(1), 44-52. [http://dx. doi.org/10.1037/0022-006X.65.1.44]. [PMID: 9103733].
[80]
Foa, E.B.; Liebowitz, M.R.; Kozak, M.J.; Davies, S.; Campeas, R.; Franklin, M.E.; Huppert, J.D.; Kjernisted, K.; Rowan, V.; Schmidt, A.B.; Simpson, H.B.; Tu, X. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 2005, 162(1), 151-161. [http://dx.doi.org/10.1176/appi. ajp.162.1.151]. [PMID: 15625214].
[81]
Fallon, B.A.; Mathew, S.J. Biological therapies for obsessive-compulsive disorder. J. Psychiatr. Pract., 2000, 6(3), 113-128. [http://dx.doi.org/10.1097/00131746-200005000-00002]. [PMID: 15990479].
[82]
Jenike, M.A.; Baer, L.; Summergrad, P.; Weilburg, J.B.; Holland, A.; Seymour, R. Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients. Am. J. Psychiatry, 1989, 146(10), 1328-1330. [http://dx.doi.org/10.1176/ ajp.146.10.1328]. [PMID: 2675643].
[83]
Greist, J.H.; Jefferson, J.W.; Rosenfeld, R.; Gutzmann, L.D.; March, J.S.; Barklage, N.E. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients. J. Clin. Psychiatry, 1990, 51(7), 292-297. [PMID: 2195006].
[84]
Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1991, 48(8), 730-738. [http://dx.doi.org/10.1001/archpsyc.1991.01810320054008]. [PMID: 1883256].
[85]
Hoehn-Saric, R.; McLeod, D.R.; Zimmerli, W.D.; Hipsley, P.A. Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine. J. Clin. Psychiatry, 1993, 54(7), 272-276. [PMID: 8335655].
[86]
Mavissakalian, M.R.; Jones, B.; Olson, S.; Perel, J.M. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J. Clin. Psychopharmacol., 1990, 10(4), 261-268. [http://dx.doi.org/10.1097/00004714-199008000-00005]. [PMID: 2286699].
[87]
Albert, U.; Aguglia, E.; Maina, G.; Bogetto, F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J. Clin. Psychiatry, 2002, 63(11), 1004-1009. [http://dx.doi.org/10.4088/JCP. v63n1108]. [PMID: 12444814].
[88]
Rauch, S.L.; O’Sullivan, R.L.; Jenike, M.A. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases. J. Clin. Psychopharmacol., 1996, 16(1), 81-84. [http://dx. doi.org/10.1097/00004714-199602000-00017]. [PMID: 8834427].
[89]
Sevincok, L.; Uygur, B. Venlafaxine open-label treatment of patients with obsessive-compulsive disorder. Aust. N. Z. J. Psychiatry, 2002, 36(6), 817. [http://dx.doi.org/10.1046/j.1440-1614.2002. t01-5-01101c.x]. [PMID: 12406128].
[90]
Hollander, E.; Friedberg, J.; Wasserman, S.; Allen, A.; Birnbaum, M.; Koran, L.M. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry, 2003, 64(5), 546-550. [http://dx.doi.org/10.4088/JCP.v64n0508]. [PMID: 12755657].
[91]
Liebowitz, M.R.; Gelenberg, A.J.; Munjack, D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch. Gen. Psychiatry, 2005, 62(2), 190-198. [http://dx.doi.org/10. 1001/archpsyc.62.2.190]. [PMID: 15699296].
[92]
Stein, M.B.; Pollack, M.H.; Bystritsky, A.; Kelsey, J.E.; Mangano, R.M. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl.), 2005, 177(3), 280-288. [http://dx.doi.org/10.1007/s00213-004-1957-9]. [PMID: 15258718].
[93]
Denys, D.; van der Wee, N.; van Megen, H.J.; Westenberg, H.G. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J. Clin. Psychopharmacol., 2003, 23(6), 568-575. [http://dx.doi.org/10.1097/01.jcp.0000095342.32154.54]. [PMID: 14624187].
[94]
Luís Blay, S.; Black, D.W. A case of obsessive-compulsive disorder responding to duloxetine. Prim. Care Companion J. Clin. Psychiatry, 2007, 9(3), 234-235. [http://dx.doi.org/10.4088/PCC. v09n0311c]. [PMID: 17632660].
[95]
Dell’osso, B.; Mundo, E.; Marazziti, D.; Altamura, A.C. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J. Psychopharmacol. (Oxford), 2008, 22(2), 210-213. [http://dx.doi.org/10. 1177/0269881107079865]. [PMID: 18208931].
[96]
Yeh, Y.W.; Chen, C.H.; Kuo, S.C.; Wang, S.C.; Chen, C.K.; Feng, H.M. High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission. Clin. Neuropharmacol., 2009, 32(3), 174-176. [http://dx.doi.org/10. 1097/WNF.0b013e31817f8cef]. [PMID: 19483491].
[97]
Yoshida, K.; Higuchi, H.; Ozaki, N. Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine. Pharmacopsychiatry, 2007, 40(2), 84-85. [http:// dx.doi.org/10.1055/s-2007-970061]. [PMID: 17447181].
[98]
De Berardis, D.; Conti, C.M.; Marini, S.; Ferri, F.; Iasevoli, F.; Valchera, A.; Fornaro, M.; Cavuto, M.; Srinivasan, V.; Perna, G.; Carano, A.; Piersanti, M.; Martinotti, G.; Di Giannantonio, M. Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data. Int. J. Immunopathol. Pharmacol., 2013, 26(2), 299-304. [http://dx.doi.org/10.1177/039463201302600203]. [PMID: 23755745].
[99]
Fornaro, M. Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series. Ann. Gen. Psychiatry, 2011, 10(1), 5. [http://dx.doi.org/10.1186/1744-859X-10-5]. [PMID: 21356085].
[100]
Tzavellas, E.; Karaiskos, D.; Ilias, I.; Liappas, I.; Paparrigopoulos, T. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report. Psychiatriki, 2014, 25(3), 179-184. [PMID: 25367661].
[101]
Roca, A.; Garcia-Esteve, L.; Imaz, M.L.; Torres, A.; Hernández, S.; Botet, F.; Gelabert, E.; Subirà, S.; Plaza, A.; Valdés, M.; Martin-Santos, R. Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose. J. Affect. Disord., 2011, 135(1-3), 208-215. [http://dx.doi. org/10.1016/j.jad.2011.07.022]. [PMID: 21890210].
[102]
Koran, L.M.; Gamel, N.N.; Choung, H.W.; Smith, E.H.; Aboujaoude, E.N. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J. Clin. Psychiatry, 2005, 66(4), 515-520. [http://dx.doi.org/10.4088/JCP. v66n0415]. [PMID: 15816795].
[103]
Pigott, T.A.; L’Heureux, F.; Rubenstein, C.S.; Bernstein, S.E.; Hill, J.L.; Murphy, D.L. A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. J. Clin. Psychopharmacol., 1992, 12(3), 156-162.
[104]
McDougle, C.J.; Epperson, C.N.; Pelton, G.H.; Wasylink, S.; Price, L.H. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch. Gen. Psychiatry, 2000, 57(8), 794-801. [http://dx.doi.org/10.1001/archpsyc.57.8.794]. [PMID: 10920469].
[105]
Ravindran, L.N.; Jung, S.M.; Ravindran, A.V. Intravenous anti-obsessive agents: a review. J. Psychopharmacol. (Oxford), 2010, 24(3), 287-296. [http://dx.doi.org/10.1177/0269881108096508]. [PMID: 18801828].
[106]
Pallanti, S.; Quercioli, L.; Koran, L.M. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J. Clin. Psychiatry, 2002, 63(9), 796-801. [http://dx.doi.org/10.4088/ JCP.v63n0908]. [PMID: 12363120].
[107]
Fallon, B.A.; Liebowitz, M.R.; Campeas, R.; Schneier, F.R.; Marshall, R.; Davies, S.; Goetz, D.; Klein, D.F. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch. Gen. Psychiatry, 1998, 55(10), 918-924. [http://dx.doi.org/10.1001/archpsyc.55.10. 918]. [PMID: 9783563].
[108]
Koran, L.M.; Sallee, F.R.; Pallanti, S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am. J. Psychiatry, 1997, 154(3), 396-401. [http://dx.doi.org/10. 1176/ajp.154.3.396]. [PMID: 9054789].
[109]
Rabinowitz, I.; Baruch, Y.; Barak, Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 2008, 23(1), 49-53. [http://dx.doi.org/10.1097/YIC. 0b013e3282f0f0c5]. [PMID: 18090508].
[110]
Dougherty, D.D.; Jameson, M.; Deckersbach, T.; Loh, R.; Thompson-Hollands, J.; Jenike, M.; Keuthen, N.J. Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 2009, 24(6), 306-311. [http://dx.doi.org/10.1097/YIC. 0b013e32833119d8]. [PMID: 19730388].
[111]
Hollander, E.; Bienstock, C.A.; Koran, L.M.; Pallanti, S.; Marazziti, D.; Rasmussen, S.A.; Ravizza, L.; Benkelfat, C.; Saxena, S.; Greenberg, B.D.; Sasson, Y.; Zohar, J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J. Clin. Psychiatry, 2002, 63(Suppl. 6), 20-29. [PMID: 12027116].
[112]
Denys, D.; Zohar, J.; Westenberg, H.G. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J. Clin. Psychiatry, 2004, 65(Suppl. 14), 11-17. [PMID: 15554783].
[113]
Schirmbeck, F.; Zink, M. Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front. Pharmacol., 2013, 4, 99. [http://dx.doi.org/10. 3389/fphar.2013.00099]. [PMID: 23950745].
[114]
Gordon, A. Transition of obsessions into delusions. Evaluation of obsessional phenomena from the prognostic standpoint. Am. J. Psychiatry, 1950, 107(6), 455-458. [http://dx.doi.org/10.1176/ ajp.107.6.455]. [PMID: 14838150].
[115]
Klemperer, F. Compulsions developing into command hallucinations. Psychopathology, 1996, 29(4), 249-251. [http://dx.doi.org/ 10.1159/000285001]. [PMID: 8865357].
[116]
Devi, S.; Rao, N.P.; Badamath, S.; Chandrashekhar, C.R.; Janardhan Reddy, Y.C. Prevalence and clinical correlates of obsessive-compulsive disorder in schizophrenia. Compr. Psychiatry, 2015, 56, 141-148. [http://dx.doi.org/10.1016/j.comppsych.2014.09.015]. [PMID: 25308405].
[117]
Kapur, S.; Remington, G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry, 1996, 153(4), 466-476. [http://dx.doi.org/10.1176/ajp.153.4.466]. [PMID: 8599393].
[118]
Pollitt, J.D. Natural history studies in mental illness. A discussion based on a pilot study of obsessional states. J. Ment. Sci., 1960, 106, 93-113. [http://dx.doi.org/10.1192/bjp.106.442.93]. [PMID: 14433876].
[119]
Ingram, I.M. Obsessional illness in mental hospital patients. J. Ment. Sci., 1961, 107, 382-402. [http://dx.doi.org/10.1192/bjp.107. 448.382]. [PMID: 13717718].
[120]
Lo, W.H. A follow-up study of obsessional neurotics in Hong Kong Chinese. Br. J. Psychiatry, 1967, 113(501), 823-832. [http://dx.doi.org/10.1192/bjp.113.501.823]. [PMID: 6048368].
[121]
Welner, A.; Reich, T.; Robins, E.; Fishman, R.; Van Doren, T. Obsessive-compulsive neurosis: record, follow-up, and family studies. I. Inpatient record study. Compr. Psychiatry, 1976, 17(4), 527-539. [http://dx.doi.org/10.1016/0010-440X(76)90035-3]. [PMID: 963994].
[122]
Jenike, M.A.; Baer, L.; Minichiello, W.E.; Schwartz, C.E.; Carey, R.J., Jr Coexistent obsessive-compulsive disorder and schizotypal personality disorder: a poor prognostic indicator. Arch. Gen. Psychiatry, 1986, 43(3), 296. [http://dx.doi.org/10.1001/archpsyc. 1986.01800030114016]. [PMID: 3954553].
[123]
Joffe, R.T.; Swinson, R.P.; Regan, J.J. Personality features of obsessive-compulsive disorder. Am. J. Psychiatry, 1988, 145(9), 1127-1129. [http://dx.doi.org/10.1176/ajp.145.9.1127]. [PMID: 3414855].
[124]
Baer, L.; Jenike, M.A.; Ricciardi, J.N., II; Holland, A.D.; Seymour, R.J.; Minichiello, W.E.; Buttolph, M.L. Standardized assessment of personality disorders in obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1990, 47(9), 826-830. [http://dx.doi.org/10.1001/ archpsyc.1990.01810210034005]. [PMID: 2393341].
[125]
Ganesan, V.; Kumar, T.C.; Khanna, S. Obsessive--compulsive disorder and psychosis. Can. J. Psychiatry, 2001, 46(8), 750-754. [http://dx.doi.org/10.1177/070674370104600809]. [PMID: 11692979].
[126]
American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Obsessive-Compulsive Disorder; American Psychiatric Association: Arlington, VA, 2007.
[127]
Bandelow, B.; Zohar, J.; Hollander, E.; Kasper, S.; Möller, H.J.; Zohar, J.; Hollander, E.; Kasper, S.; Möller, H.J.; Bandelow, B.; Allgulander, C.; Ayuso-Gutierrez, J.; Baldwin, D.S.; Buenvicius, R.; Cassano, G.; Fineberg, N.; Gabriels, L.; Hindmarch, I.; Kaiya, H.; Klein, D.F.; Lader, M.; Lecrubier, Y.; Lépine, J.P.; Liebowitz, M.R.; Lopez-Ibor, J.J.; Marazziti, D.; Miguel, E.C.; Oh, K.S.; Preter, M.; Rupprecht, R.; Sato, M.; Starcevic, V.; Stein, D.J.; van Ameringen, M.; Vega, J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J. Biol. Psychiatry, 2008, 9(4), 248-312. [http://dx.doi.org/10.1080/15622970802465807]. [PMID: 18949648].
[128]
Van Ameringen, M.; Simpson, W.; Patterson, B.; Dell’Osso, B.; Fineberg, N.; Hollander, E.; Hranov, L.; Hranov, G.; Lochner, C.; Karamustafalioglu, O.; Marazziti, D.; Menchon, J.M.; Nicolini, H.; Pallanti, S.; Stein, D.J.; Zohar, J. Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. J. Psychopharmacol. (Oxford), 2014, 28(6), 596-602. [http://dx.doi.org/10.1177/0269881113517955]. [PMID: 24429223].
[129]
Phillips, K.A. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am. J. Psychiatry, 2005, 162(2), 377-379. [http://dx.doi.org/10.1176/appi.ajp.162.2.377]. [PMID: 15677604].
[130]
Albert, U.; Carmassi, C.; Cosci, F.; De Cori, D.; Di Nicola, M.; Ferrari, S.; Poloni, N.; Tarricone, I.; Fiorillo, A. Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review. Int. Clin. Psychopharmacol., 2016, 31(5), 249-258. [http://dx.doi.org/10.1097/YIC. 0000000000000127]. [PMID: 26974213].
[131]
Albert, U.; Marazziti, D.; Di Salvo, G.; Solia, F.; Rosso, G.; Maina, G. A systematic review of evidence-based treatment strategies for obsessive-compulsive disorder resistant to first-line pharmacotherapy. Curr. Med. Chem., 2018, 25(41), 5647-5661. [http://dx. doi.org/10.2174/0929867325666171222163645]. [PMID: 29278206].
[132]
Komossa, K.; Depping, A.M.; Meyer, M.; Kissling, W.; Leucht, S. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst. Rev., 2010, 12(12)CD008141 [PMID: 21154394].
[133]
Dold, M.; Aigner, M.; Lanzenberger, R.; Kasper, S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int. J. Neuropsychopharmacol., 2013, 16(3), 557-574. [http://dx.doi.org/10.1017/S146114571 2000740]. [PMID: 22932229].
[134]
Li, X.; May, R.S.; Tolbert, L.C.; Jackson, W.T.; Flournoy, J.M.; Baxter, L.R. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J. Clin. Psychiatry, 2005, 66(6), 736-743. [http://dx.doi.org/10.4088/JCP.v66n0610]. [PMID: 15960567].
[135]
Hollander, E.; Baldini, R.N.; Sood, E.; Pallanti, S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol., 2003, 6(4), 397-401. [http://dx.doi.org/10.1017/S14611 45703003730]. [PMID: 14604454].
[136]
Buchsbaum, M.S.; Hollander, E.; Pallanti, S.; Baldini, R.N.; Platholi, J.; Newmark, R.; Bloom, R.; Sood, E. Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients. Neuropsychobiology, 2006, 53(3), 157-168. [http://dx.doi.org/10.1159/000093342]. [PMID: 16707915].
[137]
Erzegovesi, S.; Guglielmo, E.; Siliprandi, F.; Bellodi, L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur. Neuropsychopharmacol., 2005, 15(1), 69-74. [http://dx.doi.org/10. 1016/j.euroneuro.2004.04.004]. [PMID: 15572275].
[138]
Simpson, H.B.; Foa, E.B.; Liebowitz, M.R.; Huppert, J.D.; Cahill, S.; Maher, M.J.; McLean, C.P.; Bender, J., Jr; Marcus, S.M.; Williams, M.T.; Weaver, J.; Vermes, D.; Van Meter, P.E.; Rodriguez, C.I.; Powers, M.; Pinto, A.; Imms, P.; Hahn, C.G.; Campeas, R. Cognitive-behavioral therapy vs. risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. JAMA Psychiatry, 2013, 70(11), 1190-1199. [http://dx.doi.org/10.1001/jamapsychiatry.2013.1932]. [PMID: 24026523].
[139]
Savas, H.A.; Yumru, M.; Ozen, M.E. Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study. Clin. Drug Investig., 2008, 28(7), 439-442. [http://dx.doi.org/10.2165/00044011-200828070-00005]. [PMID: 18544004].
[140]
Maina, G.; Pessina, E.; Albert, U.; Bogetto, F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur. Neuropsychopharmacol., 2008, 18(5), 364-372. [http://dx.doi.org/10.1016/j.euroneuro.2008. 01.001]. [PMID: 18280710].
[141]
Selvi, Y.; Atli, A.; Aydin, A.; Besiroglu, L.; Ozdemir, P.; Ozdemir, O. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. Hum. Psychopharmacol., 2011, 26(1), 51-57. [http://dx.doi.org/10.1002/hup. 1169]. [PMID: 21308781].
[142]
Vulink, N.C.; Denys, D.; Fluitman, S.B.; Meinardi, J.C.; Westenberg, H.G. Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. J. Clin. Psychiatry, 2009, 70(7), 1001-1008. [http://dx.doi.org/10.4088/JCP.08m04269]. [PMID: 19497245].
[143]
Fineberg, N.A.; Sivakumaran, T.; Roberts, A.; Gale, T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int. Clin. Psychopharmacol., 2005, 20(4), 223-226. [http://dx.doi.org/10.1097/ 00004850-200507000-00005]. [PMID: 15933483].
[144]
Atmaca, M.; Kuloglu, M.; Tezcan, E.; Gecici, O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int. Clin. Psychopharmacol., 2002, 17(3), 115-119. [http://dx.doi.org/10.1097/ 00004850-200205000-00004]. [PMID: 11981352].
[145]
Denys, D.; de Geus, F.; van Megen, H.J.; Westenberg, H.G. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J. Clin. Psychiatry, 2004, 65(8), 1040-1048. [http://dx.doi.org/10.4088/JCP.v65n0803]. [PMID: 15323587].
[146]
Carey, P.D.; Vythilingum, B.; Seedat, S.; Muller, J.E.; van Ameringen, M.; Stein, D.J. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study.[ISRCTN83050762]. BMC Psychiatry, 2005, 5(5), 5. [http://dx.doi.org/10.1186/1471-244X-5-5]. [PMID: 15667657].
[147]
Kordon, A.; Wahl, K.; Koch, N.; Zurowski, B.; Anlauf, M.; Vielhaber, K.; Kahl, K.G.; Broocks, A.; Voderholzer, U.; Hohagen, F. Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J. Clin. Psychopharmacol., 2008, 28(5), 550-554. [http://dx.doi.org/10.1097/JCP.0b013e318185e735]. [PMID: 18794652].
[148]
Dold, M.; Aigner, M.; Lanzenberger, R.; Kasper, S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int. J. Neuropsychopharmacol., 2015, 18(9) [http://dx.doi.org/10.1093/ijnp/pyv047].
[149]
Veale, D.; Miles, S.; Smallcombe, N.; Ghezai, H.; Goldacre, B.; Hodsoll, J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry, 2014, 14, 317. [http://dx.doi. org/10.1186/s12888-014-0317-5]. [PMID: 25432131].
[150]
McDougle, C.J.; Goodman, W.K.; Leckman, J.F.; Lee, N.C.; Heninger, G.R.; Price, L.H. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry, 1994, 51(4), 302-308. [http://dx.doi.org/10.1001/archpsyc. 1994.03950040046006]. [PMID: 8161290].
[151]
Mohr, N.; Vythilingum, B.; Emsley, R.A.; Stein, D.J. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 2002, 17(1), 37-40. [http://dx.doi.org/10.1097/00004850-200201000-00006]. [PMID: 11800505].
[152]
Bogetto, F.; Bellino, S.; Vaschetto, P.; Ziero, S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res., 2000, 96(2), 91-98. [http://dx.doi.org/10.1016/S0165-1781(00)00203-1]. [PMID: 11063782].
[153]
Metin, O.; Yazici, K.; Tot, S.; Yazici, A.E. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum. Psychopharmacol., 2003, 18(6), 463-467. [http://dx. doi.org/10.1002/hup.512]. [PMID: 12923825].
[154]
Uguz, F. Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder. Gen. Hosp. Psychiatry, 2010, 32(5), 556-558. [http://dx.doi.org/10. 1016/j.genhosppsych.2010.07.004]. [PMID: 20851277].
[155]
Glick, I.D.; Poyurovsky, M.; Ivanova, O.; Koran, L.M. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. J. Clin. Psychiatry, 2008, 69(12), 1856-1859. [http://dx.doi.org/10.4088/JCP.v69n1202]. [PMID: 19026264].
[156]
Murphy, T.K.; Mutch, P.J.; Reid, J.M.; Edge, P.J.; Storch, E.A.; Bengtson, M.; Yang, M. Open label aripiprazole in the treatment of youth with tic disorders. J. Child Adolesc. Psychopharmacol., 2009, 19(4), 441-447. [http://dx.doi.org/10.1089/cap.2008.0149]. [PMID: 19702496].
[157]
Connor, K.M.; Payne, V.M.; Gadde, K.M.; Zhang, W.; Davidson, J.R. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J. Clin. Psychiatry, 2005, 66(1), 49-51. [http://dx.doi.org/10.4088/JCP.v66n0107]. [PMID: 15669888].
[158]
da Rocha, F.F.; Correa, H. Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(7), 1550-1551. [http://dx.doi.org/10.1016/j.pnpbp.2007.07.008]. [PMID: 17692447].
[159]
Sarkar, R.; Klein, J.; Krüger, S. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. Psychopharmacology (Berl.), 2008, 197(4), 687-688. [http://dx.doi.org/ 10.1007/s00213-008-1091-1]. [PMID: 18264798].
[160]
Fornaro, M.; Gabrielli, F.; Mattei, C.; Vinciguerra, V.; Fornaro, P. Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report. Ann. Gen. Psychiatry, 2008, 7, 26. [http://dx.doi.org/10.1186/1744-859X-7-26]. [PMID: 19105842].
[161]
Storch, E.A.; Lehmkuhl, H.; Geffken, G.R.; Touchton, A.; Murphy, T.K. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress. Anxiety, 2008, 25(2), 172-174. [http://dx.doi.org/10.1002/ da.20303]. [PMID: 17340610].
[162]
Pessina, E.; Albert, U.; Bogetto, F.; Maina, G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int. Clin. Psychopharmacol., 2009, 24(5), 265-269. [http:// dx.doi.org/10.1097/YIC.0b013e32832e9b91]. [PMID: 19629012].
[163]
Masi, G.; Pfanner, C.; Millepiedi, S.; Berloffa, S. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J. Clin. Psychopharmacol., 2010, 30(6), 688-693. [http://dx.doi.org/10.1097/JCP.0b013e3181fab7b1]. [PMID: 21105283].
[164]
Delle Chiaie, R.; Scarciglia, P.; Pasquini, M.; Caredda, M.; Biondi, M. Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study. Clin. Pract. Epidemiol. Ment. Health, 2011, 7, 107-111. [http://dx.doi.org/10.2174/17450179011 07010107]. [PMID: 21686322].
[165]
Matsunaga, H.; Hayashida, K.; Maebayashi, K.; Mito, H.; Kiriike, N. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder. Int. J. Psychiatry Clin. Pract., 2011, 15(4), 263-269. [http:// dx.doi.org/10.3109/13651501.2011.605958]. [PMID: 22121999].
[166]
Muscatello, M.R.; Bruno, A.; Pandolfo, G.; Micò, U.; Scimeca, G.; Romeo, V.M.; Santoro, V.; Settineri, S.; Spina, E.; Zoccali, R.A. Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J. Clin. Psychopharmacol., 2011, 31(2), 174-179. [http://dx.doi.org/10.1097/JCP. 0b013e31820e3db6]. [PMID: 21346614].
[167]
Sayyah, M.; Sayyah, M.; Boostani, H.; Ghaffari, S.M.; Hoseini, A. Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress. Anxiety, 2012, 29(10), 850-854. [http://dx.doi.org/10.1002/da. 21996]. [PMID: 22933237].
[168]
Leucht, S.; Cipriani, A.; Spineli, L.; Mavridis, D.; Orey, D.; Richter, F.; Samara, M.; Barbui, C.; Engel, R.R.; Geddes, J.R.; Kissling, W.; Stapf, M.P.; Lässig, B.; Salanti, G.; Davis, J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 2013, 382(9896), 951-962. [http://dx.doi.org/10.1016/S0140-6736(13)60733-3]. [PMID: 23810019].
[169]
Storch, E.A.; Goddard, A.W.; Grant, J.E.; De Nadai, A.S.; Goodman, W.K.; Mutch, P.J.; Medlock, C.; Odlaug, B.; McDougle, C.J.; Murphy, T.K. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J. Clin. Psychiatry, 2013, 74(6), e527-e532. [http://dx.doi.org/10.4088/JCP.12m08278]. [PMID: 23842022].
[170]
McDougle, C.J.; Barr, L.C.; Goodman, W.K.; Pelton, G.H.; Aronson, S.C.; Anand, A.; Price, L.H. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am. J. Psychiatry, 1995, 152(12), 1812-1814. [http://dx.doi.org/10.1176/ ajp.152.12.1812]. [PMID: 8526253].
[171]
Englisch, S.; Esslinger, C.; Inta, D.; Weinbrenner, A.; Peus, V.; Gutschalk, A.; Schirmbeck, F.; Zink, M. Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. Clin. Neuropharmacol., 2009, 32(4), 227-229. [http://dx.doi. org/10.1097/WNF.0b013e31819cc8e6]. [PMID: 19644230].
[172]
Sa, A.R.; Hounie, A.G.; Sampaio, A.S.; Arrais, J.; Miguel, E.C.; Elkis, H. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Compr. Psychiatry, 2009, 50(5), 437-442. [http://dx.doi.org/10.1016/j. comppsych.2008.11.005]. [PMID: 19683614].
[173]
Scheltema Beduin, A.A.; Swets, M.; Machielsen, M.; Korver, N. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. J. Clin. Psychiatry, 2012, 73(11), 1395-1402. [http://dx.doi.org/10. 4088/JCP.11m07164]. [PMID: 23218156].
[174]
Gahr, M.; Rehbaum, K.; Connemann, B.J. Clozapine-associated development of second-onset obsessive compulsive symptoms in schizophrenia: impact of clozapine serum levels and fluvoxamine add-on. Pharmacopsychiatry, 2014, 47(3), 118-120. [http://dx. doi.org/10.1055/s-0034-1374611]. [PMID: 24846087].
[175]
Grover, S.; Hazari, N.; Chakrabarti, S.; Avasthi, A. Relationship of obsessive compulsive symptoms/disorder with clozapine: A retrospective study from a multispeciality tertiary care centre. Asian J. Psychiatr., 2015, 15, 56-61. [http://dx.doi.org/10.1016/j.ajp.2015. 05.002]. [PMID: 26013671].
[176]
Schirmbeck, F.; Mier, D.; Esslinger, C.; Rausch, F.; Englisch, S.; Eifler, S.; Meyer-Lindenberg, A.; Kirsch, P.; Zink, M. Increased orbitofrontal cortex activation associated with “pro-obsessive” antipsychotic treatment in patients with schizophrenia. J. Psychiatry Neurosci., 2015, 40(2), 89-99. [PMID: 25268790].
[177]
Schirmbeck, F.; Zink, M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr. Neuropharmacol., 2012, 10(1), 88-95. [http://dx.doi.org/10.2174/1570159127 99362724]. [PMID: 22942882].
[178]
Levkovitch, Y.; Kronnenberg, Y.; Gaoni, B. Can clozapine trigger OCD? J. Am. Acad. Child Adolesc. Psychiatry, 1995, 34(3), 263. [http://dx.doi.org/10.1097/00004583-199503000-00005]. [PMID: 7896662].
[179]
Eales, M.J.; Layeni, A.O. Exacerbation of obsessive-compulsive symptoms associated with clozapine. Br. J. Psychiatry, 1994, 164(5), 687-688. [http://dx.doi.org/10.1192/bjp.164.5.687]. [PMID: 7921724].
[180]
Leung, J.G.; Palmer, B.A. Psychosis or Obsessions? Clozapine Associated with Worsening Obsessive-Compulsive Symptoms. Case Rep. Psychiatry, 2016, 20162180748 [http://dx.doi.org/ 10.1155/2016/2180748]. [PMID: 27313938].
[181]
Del Casale, A.; Kotzalidis, G.D.; Rapinesi, C.; Serata, D.; Ambrosi, E.; Simonetti, A.; Pompili, M.; Ferracuti, S.; Tatarelli, R.; Girardi, P. Functional neuroimaging in obsessive-compulsive disorder. Neuropsychobiology, 2011, 64(2), 61-85. [http://dx.doi.org/10. 1159/000325223]. [PMID: 21701225].
[182]
Del Casale, A.; Rapinesi, C.; Kotzalidis, G.D.; De Rossi, P.; Curto, M.; Janiri, D.; Criscuolo, S.; Alessi, M.C.; Ferri, V.R.; De Giorgi, R.; Sani, G.; Ferracuti, S.; Girardi, P.; Brugnoli, R. Executive functions in obsessive-compulsive disorder: An activation likelihood estimate meta-analysis of fMRI studies. World J. Biol. Psychiatry, 2016, 17(5), 378-393. [http://dx.doi.org/10.3109/15622975.2015. 1102323]. [PMID: 26642972].
[183]
Schirmbeck, F.; Esslinger, C.; Rausch, F.; Englisch, S.; Meyer-Lindenberg, A.; Zink, M. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol. Med., 2011, 41(11), 2361-2373. [http://dx.doi.org/10.1017/ S0033291711000419]. [PMID: 21466748].
[184]
Cai, J.; Zhang, W.; Yi, Z.; Lu, W.; Wu, Z.; Chen, J.; Yu, S.; Fang, Y.; Zhang, C. Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology (Berl.), 2013, 230(1), 49-55. [http://dx.doi.org/10.1007/s00213-013-3137-2]. [PMID: 23660601].
[185]
Lin, S.K.; Su, S.F.; Pan, C.H. Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms. Ther. Drug Monit., 2006, 28(3), 303-307. [http://dx.doi.org/10.1097/01.ftd.0000211801.66569.80]. [PMID: 16778711].
[186]
Andrade, C. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia. J. Clin. Psychiatry, 2012, 73(11), e1362-e1364. [http://dx.doi.org/ 10.4088/JCP.12f08200]. [PMID: 23218164].
[187]
Eryılmaz, G.; Hızlı Sayar, G.; Ozten, E.; Gögcegöz Gül, I.; Karamustafalıoğlu, O. Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia. Ann. Gen. Psychiatry, 2013, 12(1), 40. [http://dx.doi.org/10.1186/1744-859X-12-40]. [PMID: 24330737].
[188]
Cassady, S.L.; Thaker, G.K. Addition of fluoxetine to clozapine. Am. J. Psychiatry, 1992, 149(9), 1274. [PMID: 1503143].
[189]
Strous, R.D.; Patel, J.K.; Zimmet, S.; Green, A.I. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features. Am. J. Psychiatry, 1999, 156(6), 973-974. [http://dx.doi.org/10.1176/ajp.156.6.973a]. [PMID: 10360153].
[190]
Markowitz, J.S.; Gill, H.S.; Lavia, M.; Brewerton, T.D.; DeVane, C.L. Fluvoxamine-clozapine dose-dependent interaction. Can. J. Psychiatry, 1996, 41(10), 670-671. [http://dx.doi.org/10.1177/ 070674379604101027]. [PMID: 8978949].
[191]
Zink, M.; Englisch, S.; Knopf, U.; Kuwilsky, A.; Dressing, H. Augmentation of clozapine with valproic Acid for clozapine-induced obsessive-compulsive symptoms. Pharmacopsychiatry, 2007, 40(5), 202-203. [http://dx.doi.org/10.1055/s-2007-985885]. [PMID: 17874353].
[192]
Rao, N.P.; Antony, A.; Raveendranathan, D.; Venkatasubramanian, G.; Behere, R.V.; Varambally, S.S.; Gangadhar, B.N. Successful use of maintenance electroconvulsive therapy in the treatment of clozapine-associated obsessive-compulsive symptoms in schizophrenia: a case report. J. ECT, 2011, 27(1), e37-e38. [http://dx. doi.org/10.1097/YCT.0b013e3181ec0d64]. [PMID: 20938347].
[193]
Kapur, S.; Zipursky, R.B.; Remington, G.; Jones, C.; DaSilva, J.; Wilson, A.A.; Houle, S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry, 1998, 155(7), 921-928. [http://dx.doi.org/10.1176/ajp.155.7.921]. [PMID: 9659858].
[194]
Bloch, M.H.; Landeros-Weisenberger, A.; Kelmendi, B.; Coric, V.; Bracken, M.B.; Leckman, J.F. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol. Psychiatry, 2006, 11(7), 622-632. [http://dx.doi.org/10. 1038/sj.mp.4001823]. [PMID: 16585942].
[195]
Matsunaga, H.; Nagata, T.; Hayashida, K.; Ohya, K.; Kiriike, N.; Stein, D.J. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. J. Clin. Psychiatry, 2009, 70(6), 863-868. [http://dx.doi.org/10.4088/JCP.08m04369]. [PMID: 19422759].
[196]
Diniz, J.B.; Shavitt, R.G.; Fossaluza, V.; Koran, L.; Pereira, C.A.; Miguel, E.C. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J. Clin. Psychopharmacol., 2011, 31(6), 763-768. [http://dx.doi.org/10.1097/JCP. 0b013e3182367aee]. [PMID: 22020357].
[197]
Pallanti, S.; Quercioli, L.; Paiva, R.S.; Koran, L.M. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur. Psychiatry, 1999, 14(2), 101-106. [http://dx.doi.org/10.1016/S0924-9338(99) 80725-1]. [PMID: 10572334].
[198]
Neuvonen, P.J.; Pohjola-Sintonen, S.; Tacke, U.; Vuori, E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet, 1993, 342(8884), 1419. [http://dx.doi.org/10.1016/0140-6736(93)92774-N]. [PMID: 7901695].
[199]
Rosebush, P.I.; Margetts, P.; Mazurek, M.F. Serotonin syndrome as a result of clomipramine monotherapy. J. Clin. Psychopharmacol., 1999, 19(3), 285-287. [http://dx.doi.org/10.1097/00004714-199906000-00021]. [PMID: 10350043].
[200]
Carey, P.D.; Lochner, C.; Kidd, M.; Van Ameringen, M.; Stein, D.J.; Denys, D. Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable? Int. Clin. Psychopharmacol., 2012, 27(6), 321-325. [PMID: 22859064].
[201]
Berlin, H.A.; Koran, L.M.; Jenike, M.A.; Shapira, N.A.; Chaplin, W.; Pallanti, S.; Hollander, E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry, 2011, 72(5), 716-721. [http://dx.doi.org/10.4088/JCP.09m05266gre]. [PMID: 20816027].
[202]
Mowla, A.; Khajeian, A.M.; Sahraian, A.; Chohedri, A.H.; Kashkoli, F. Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial. CNS Spectr., 2010, 15(11), 613-617. [http://dx.doi.org/10.1017/S1092852912000065]. [PMID: 24726048].
[203]
Rubio, A.; Jiménez-Arriero, M.A.; Martínez-Gras, I.; Manzanares, J.; Palomo , T. The effects of topiramate adjunctive treatment addedto antidepressants in patients with resistant obsessive-compulsive disorder. J. Clin. Psychopharmacol.., 2006, 26(3), 341-344. [PMID: 16702907].
[204]
Afshar, H.; Akuchekian, S.; Mahaky, B.; Zarean, E. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. J. Res. Med. Sci., 2014, 19(10), 976-981. [PMID: 25538783].
[205]
Oulis, P.; Mourikis, I.; Konstantakopoulos, G. Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 2011, 26(4), 221-224. [http://dx.doi. org/10.1097/YIC.0b013e3283466657]. [PMID: 21460732].
[206]
Uzun, O. Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report. J. Psychopharmacol. (Oxford), 2010, 24(3), 425-427. [http://dx.doi.org/ 10.1177/0269881108098809]. [PMID: 19010977].
[207]
Arrojo-Romero, M.; Tajes, A.M.; de Leon, J. Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder. Case Rep. Psychiatry, 2013, 2013612459 [http://dx.doi.org/10.1155/2013/ 612459]. [PMID: 23936714].
[208]
Bruno, A.; Micò, U.; Pandolfo, G.; Mallamace, D.; Abenavoli, E.; Di Nardo, F.; D’Arrigo, C.; Spina, E.; Zoccali, R.A.; Muscatello, M.R. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J. Psychopharmacol. (Oxford), 2012, 26(11), 1456-1462. [http://dx.doi.org/10.1177/0269881111431751]. [PMID: 22351381].
[209]
Khalkhali, M.; Aram, S.; Zarrabi, H.; Kafie, M.; Heidarzadeh, A. Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial. Iran. J. Psychiatry, 2016, 11(2), 104-114. [PMID: 27437007].
[210]
Onder, E.; Tural, U.; Gökbakan, M. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder? Eur. Arch. Psychiatry Clin. Neurosci., 2008, 258(6), 319-323. [http:// dx.doi.org/10.1007/s00406-007-0798-z]. [PMID: 18297416].
[211]
Deltito, J.A. Valproate pretreatment for the difficult-to-treat patient with OCD. J. Clin. Psychiatry, 1994, 55(11), 500. [PMID: 7989288].
[212]
Corá-Locatelli, G.; Greenberg, B.D.; Martin, J.D.; Murphy, D.L. Valproate monotherapy in an SRI-intolerant OCD patient. J. Clin. Psychiatry, 1998, 59(2), 82. [http://dx.doi.org/10.4088/JCP.v59n0207b]. [PMID: 9501891].
[213]
Thompson, A.J.; Lummis, S.C. The 5-HT3 receptor as a therapeutic target. Expert Opin. Ther. Targets, 2007, 11(4), 527-540. [http://dx.doi.org/10.1517/14728222.11.4.527]. [PMID: 17373882].
[214]
Andrade, C. Nonsteroidal anti-inflammatory drugs and 5-HT3 serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia. J. Clin. Psychiatry, 2014, 75(7), e707-e709. [http://dx.doi.org/10.4088/JCP.14f09292]. [PMID: 25093487].
[215]
Toren, P.; Weizman, A.; Ratner, S.; Cohen, D.; Laor, N. Ondansetron treatment in Tourette’s disorder: a 3-week, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry, 2005, 66(4), 499-503. [http://dx.doi.org/10.4088/JCP.v66n0413]. [PMID: 15816793].
[216]
Sirota, P.; Mosheva, T.; Shabtay, H.; Giladi, N.; Korczyn, A.D. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am. J. Psychiatry, 2000, 157(2), 287-289. [http://dx.doi.org/10.1176/appi. ajp.157.2.287]. [PMID: 10671405].
[217]
Johnson, B.A.; Ait-Daoud, N.; Seneviratne, C.; Roache, J.D.; Javors, M.A.; Wang, X.Q.; Liu, L.; Penberthy, J.K.; DiClemente, C.C.; Li, M.D. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry, 2011, 168(3), 265-275. [http://dx.doi.org/ 10.1176/appi.ajp.2010.10050755]. [PMID: 21247998].
[218]
Serata, D.; Kotzalidis, G.D.; Rapinesi, C.; Janiri, D.; Di Pietro, S.; Callovini, G.; Piacentino, D.; Gasperoni, C.; Brugnoli, R.; Ferri, V.R.; Girardi, N.; Tatarelli, R.; Ferracuti, S.; Angeletti, G.; Girardi, P.; Del Casale, A. Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature. Hum. Psychopharmacol., 2015, 30(2), 70-84. [http://dx.doi.org/10.1002/ hup.2461]. [PMID: 25676060].
[219]
Hewlett, W.A.; Schmid, S.P.; Salomon, R.M. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J. Clin. Psychiatry, 2003, 64(9), 1025-1030. [http://dx.doi.org/ 10.4088/JCP.v64n0907]. [PMID: 14628977].
[220]
Pallanti, S.; Bernardi, S.; Antonini, S.; Singh, N.; Hollander, E. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs, 2009, 23(12), 1047-1055. [http://dx.doi.org/10.2165/ 11530240-000000000-00000]. [PMID: 19958042].
[221]
Pallanti, S.; Bernardi, S.; Antonini, S.; Singh, N.; Hollander, E. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur. Neuropsychopharmacol., 2014, 24(3), 375-380. [http://dx.doi.org/10.1016/j.euroneuro.2013.12.003]. [PMID: 24406025].
[222]
Soltani, F.; Sayyah, M.; Feizy, F.; Malayeri, A.; Siahpoosh, A.; Motlagh, I. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder. Hum. Psychopharmacol., 2010, 25(6), 509-513. [http://dx.doi.org/10. 1002/hup.1145]. [PMID: 20737524].
[223]
Heidari, M.; Zarei, M.; Hosseini, S.M.; Taghvaei, R.; Maleki, H.; Tabrizi, M.; Fallah, J.; Akhondzadeh, S. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 2014, 29(6), 344-350. [http://dx.doi.org/10.1097/YIC.0000000000000043]. [PMID: 24850229].
[224]
Andrade, C. Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder. J. Clin. Psychiatry, 2015, 76(1), e72-e75. [http://dx.doi.org/ 10.4088/JCP.14f09704]. [PMID: 25650682].
[225]
Shapira, N.A.; Keck, P.E., Jr; Goldsmith, T.D.; McConville, B.J.; Eis, M.; McElroy, S.L. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress. Anxiety, 1997, 6(4), 170-173. [http://dx.doi.org/10.1002/ (SICI)1520-6394(1997)6:4<170:AID-DA7>3.0.CO;2-G]. [PMID: 9559288].
[226]
Warneke, L. A possible new treatment approach to obsessive-compulsive disorder. Can. J. Psychiatry, 1997, 42(6), 667-668. [http://dx.doi.org/10.1177/070674379704200624]. [PMID: 9288436].
[227]
Goldsmith, T.B.; Shapira, N.A.; Keck, P.E. Jr Rapid remission of OCD with tramadol hydrochloride. Am. J. Psychiatry, 1999, 156(4), 660-661. [PMID: 10200754].
[228]
Koran, L.M.; Aboujaoude, E.; Bullock, K.D.; Franz, B.; Gamel, N.; Elliott, M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry, 2005, 66(3), 353-359. [http://dx.doi.org/10.4088/JCP.v66n0312]. [PMID: 15766302].
[229]
Liddell, M.B.; Aziz, V.; Briggs, P.; Kanakkehewa, N.; Rawi, O. Buprenorphine augmentation in the treatment of refractory obsessive-compulsive disorder. Ther. Adv. Psychopharmacol., 2013, 3(1), 15-19. [http://dx.doi.org/10.1177/2045125312462233]. [PMID: 23983988].
[230]
Urraca, N.; Camarena, B.; Gómez-Caudillo, L.; Esmer, M.C.; Nicolini, H. Mu opioid receptor gene as a candidate for the study of obsessive compulsive disorder with and without tics. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2004, 127B(1), 94-96. [http://dx. doi.org/10.1002/ajmg.b.20170]. [PMID: 15108189].
[231]
Rojas-Corrales, M.O.; Gibert-Rahola, J.; Mico, J.A. Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior. Psychopharmacology (Berl.), 2007, 190(2), 221-231. [http://dx.doi.org/10.1007/s00213-006-0619-5]. [PMID: 17102981].
[232]
Insel, T.R.; Pickar, D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am. J. Psychiatry, 1983, 140(9), 1219-1220. [http://dx.doi.org/10.1176/ajp.140.9.1219]. [PMID: 6614234].
[233]
Keuler, D.J.; Altemus, M.; Michelson, D.; Greenberg, B.; Murphy, D.L. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol. Psychiatry, 1996, 40(2), 154-156. [http:// dx.doi.org/10.1016/0006-3223(95)00632-X]. [PMID: 8793049].
[234]
Goff, D.C.; Tsai, G.; Levitt, J.; Amico, E.; Manoach, D.; Schoenfeld, D.A.; Hayden, D.L.; McCarley, R.; Coyle, J.T. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch. Gen. Psychiatry, 1999, 56(1), 21-27. [http://dx.doi.org/10.1001/archpsyc.56.1.21]. [PMID: 9892252].
[235]
Tsai, G.E.; Falk, W.E.; Gunther, J.; Coyle, J.T. Improved cognition in Alzheimer’s disease with short-term D-cycloserine treatment. Am. J. Psychiatry, 1999, 156(3), 467-469. [PMID: 10080566].
[236]
Otto, M.W.; Basden, S.L.; Leyro, T.M.; McHugh, R.K.; Hofmann, S.G. Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spectr., 2007, 12(1), 51-56, 59-61. [http://dx.doi.org/10.1017/ S1092852900020526]. [PMID: 17192764].
[237]
Walker, D.L.; Ressler, K.J.; Lu, K.T.; Davis, M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J. Neurosci., 2002, 22(6), 2343-2351. [http://dx.doi.org/10.1523/JNEUROSCI.22-06-02343.2002]. [PMID: 11896173].
[238]
Norberg, M.M.; Krystal, J.H.; Tolin, D.F. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol. Psychiatry, 2008, 63(12), 1118-1126. [http://dx.doi. org/10.1016/j.biopsych.2008.01.012]. [PMID: 18313643].
[239]
Rodrigues, H.; Figueira, I.; Lopes, A.; Gonçalves, R.; Mendlowicz, M.V.; Coutinho, E.S.; Ventura, P. Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis. PLoS One, 2014, 9(7)e93519 [http://dx.doi.org/10.1371/journal. pone.0093519]. [PMID: 24991926].
[240]
Andersson, E.; Hedman, E.; Enander, J.; Radu, D.D.; Ljótsson, B.; Cervenka, S.; Isung, J.; Svanborg, C.; Mataix-Cols, D.; Kaldo, V.; Andersson, G.; Lindefors, N.; Rück, C. D-cycloserine vs. placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: A randomized clinical trial. JAMA Psychiatry, 2015, 72(7), 659-667. [http://dx.doi.org/10.1001/jamapsychiatry.2015.0546]. [PMID: 25970252].
[241]
Werner-Seidler, A.; Richardson, R. Effects of D-cycloserine on extinction: consequences of prior exposure to imipramine. Biol. Psychiatry, 2007, 62(10), 1195-1197. [DOI:10.1016/j.biopsych. 2007.04.010]. [PMID: 17555721].
[242]
Mataix-Cols, D.; Fernández de la Cruz, L.; Monzani, B.; Rosenfield, D.; Andersson, E.; Pérez-Vigil, A.; Frumento, P.; de Kleine, R.A.; Difede, J.; Dunlop, B.W.; Farrell, L.J.; Geller, D.; Gerardi, M.; Guastella, A.J.; Hofmann, S.G.; Hendriks, G.J.; Kushner, M.G.; Lee, F.S.; Lenze, E.J.; Levinson, C.A.; McConnell, H.; Otto, M.W.; Plag, J.; Pollack, M.H.; Ressler, K.J.; Rodebaugh, T.L.; Rothbaum, B.O.; Scheeringa, M.S.; Siewert-Siegmund, A.; Smits, J.A.J.; Storch, E.A.; Ströhle, A.; Tart, C.D.; Tolin, D.F.; van Minnen, A.; Waters, A.M.; Weems, C.F.; Wilhelm, S.; Wyka, K.; Davis, M.; Rück, C.; Altemus, M.; Anderson, P.; Cukor, J.; Finck, C.; Geffken, G.R.; Golfels, F.; Goodman, W.K.; Gutner, C.; Heyman, I.; Jovanovic, T.; Lewin, A.B.; McNamara, J.P.; Murphy, T.K.; Norrholm, S.; Thuras, P. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data. JAMA Psychiatry, 2017, 74(5), 501-510. [http://dx.doi.org/10.1001/ jamapsychiatry.2016.3955]. [PMID: 28122091].
[243]
Kushner, M.G.; Kim, S.W.; Donahue, C.; Thuras, P.; Adson, D.; Kotlyar, M.; McCabe, J.; Peterson, J.; Foa, E.B. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol. Psychiatry, 2007, 62(8), 835-838. [http://dx.doi.org/10.1016/j. biopsych.2006.12.020]. [PMID: 17588545].
[244]
Storch, E.A.; Merlo, L.J.; Bengtson, M.; Murphy, T.K.; Lewis, M.H.; Yang, M.C.; Jacob, M.L.; Larson, M.; Hirsh, A.; Fernandez, M.; Geffken, G.R.; Goodman, W.K. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 2007, 22(4), 230-237. [http:// dx.doi.org/10.1097/YIC.0b013e32819f8480]. [PMID: 17519647].
[245]
Wilhelm, S.; Buhlmann, U.; Tolin, D.F.; Meunier, S.A.; Pearlson, G.D.; Reese, H.E.; Cannistraro, P.; Jenike, M.A.; Rauch, S.L. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am. J. Psychiatry, 2008, 165(3), 335-341. [http://dx.doi.org/10.1176/appi.ajp.2007.07050776]. [PMID: 18245177].
[246]
Storch, E.A.; Murphy, T.K.; Goodman, W.K.; Geffken, G.R.; Lewin, A.B.; Henin, A.; Micco, J.A.; Sprich, S.; Wilhelm, S.; Bengtson, M.; Geller, D.A. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol. Psychiatry, 2010, 68(11), 1073-1076. [http://dx.doi.org/10.1016/j.biopsych.2010.07.015]. [PMID: 20817153].
[247]
Mataix-Cols, D.; Turner, C.; Monzani, B.; Isomura, K.; Murphy, C.; Krebs, G.; Heyman, I. Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial. Br. J. Psychiatry, 2014, 204(1), 77-78. [http://dx.doi.org/10.1192/bjp.bp.113. 126284]. [PMID: 24262813].
[248]
Chasson, G.S.; Buhlmann, U.; Tolin, D.F.; Rao, S.R.; Reese, H.E.; Rowley, T.; Welsh, K.S.; Wilhelm, S. Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav. Res. Ther., 2010, 48(7), 675-679. [http://dx. doi.org/10.1016/j.brat.2010.03.007]. [PMID: 20362975].
[249]
Ganasen, K.A.; Ipser, J.C.; Stein, D.J. Augmentation of cognitive behavioral therapy with pharmacotherapy. Psychiatr. Clin. North Am., 2010, 33(3), 687-699. [http://dx.doi.org/10.1016/j.psc.2010. 04.008]. [PMID: 20599140].
[250]
Bontempo, A.; Panza, K.E.; Bloch, M.H. D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis. J. Clin. Psychiatry, 2012, 73(4), 533-537. [http://dx.doi.org/10.4088/JCP.11r07356]. [PMID: 22579153].
[251]
Hofmann, S.G.; Pollack, M.H.; Otto, M.W. Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine. CNS Drug Rev., 2006, 12(3-4), 208-217. [http://dx.doi.org/10. 1111/j.1527-3458.2006.00208.x]. [PMID: 17227287].
[252]
de Kleine, R.A.; Hendriks, G.J.; Kusters, W.J.; Broekman, T.G.; van Minnen, A. A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol. Psychiatry, 2012, 71(11), 962-968. [http://dx. doi.org/10.1016/j.biopsych.2012.02.033]. [PMID: 22480663].
[253]
D’Souza, D.C.; Gil, R.; Cassello, K.; Morrissey, K.; Abi-Saab, D.; White, J.; Sturwold, R.; Bennett, A.; Karper, L.P.; Zuzarte, E.; Charney, D.S.; Krystal, J.H. IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biol. Psychiatry, 2000, 47(5), 450-462. [http://dx.doi.org/10.1016/S0006-3223(99)00133-X]. [PMID: 10704956].
[254]
Quartermain, D.; Mower, J.; Rafferty, M.F.; Herting, R.L.; Lanthorn, T.H. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur. J. Pharmacol., 1994, 257(1-2), 7-12. [http://dx.doi. org/10.1016/0014-2999(94)90687-4]. [PMID: 8082709].
[255]
Boje, K.M.; Wong, G.; Skolnick, P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res., 1993, 603(2), 207-214. [http://dx.doi.org/10. 1016/0006-8993(93)91239-O]. [PMID: 8096423].
[256]
de Leeuw, A.S.; van Megen, H.J.; Kahn, R.S.; Westenberg, H.G. d-cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder. Eur. Psychiatry, 2017, 40, 38-44. [http://dx.doi.org/10.1016/j.eurpsy.2016.06.011]. [PMID: 27837671].
[257]
Marsicano, G.; Wotjak, C.T.; Azad, S.C.; Bisogno, T.; Rammes, G.; Cascio, M.G.; Hermann, H.; Tang, J.; Hofmann, C.; Zieglgänsberger, W.; Di Marzo, V.; Lutz, B. The endogenous cannabinoid system controls extinction of aversive memories. Nature, 2002, 418(6897), 530-534. [http://dx.doi.org/10.1038/nature00839]. [PMID: 12152079].
[258]
Evanson, N.K.; Tasker, J.G.; Hill, M.N.; Hillard, C.J.; Herman, J.P. Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology, 2010, 151(10), 4811-4819. [http://dx.doi.org/10.1210/en.2010-0285]. [PMID: 20702575].
[259]
Abush, H.; Akirav, I. Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory. Neuropsychopharmacology, 2013, 38(8), 1521-1534. [http:// dx.doi.org/10.1038/npp.2013.51]. [PMID: 23426383].
[260]
Micale, V.; Di Marzo, V.; Sulcova, A.; Wotjak, C.T.; Drago, F. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol. Ther., 2013, 138(1), 18-37. [http://dx. doi.org/10.1016/j.pharmthera.2012.12.002]. [PMID: 23261685].
[261]
Schier, A.R.; Ribeiro, N.P.; Silva, A.C.; Hallak, J.E.; Crippa, J.A.; Nardi, A.E.; Zuardi, A.W. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev. Bras. Psiquiatr., 2012, 34(Suppl. 1), S104-S110. [http://dx.doi.org/10.1016/S1516-4446(12)70057-0]. [PMID: 22729452].
[262]
Papini, S.; Sullivan, G.M.; Hien, D.A.; Shvil, E.; Neria, Y. Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research. Biol. Psychol., 2015, 104, 8-18. [http://dx.doi.org/10.1016/j. biopsycho.2014.10.010]. [PMID: 25448242].
[263]
Blessing, E.M.; Steenkamp, M.M.; Manzanares, J.; Marmar, C.R. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 2015, 12(4), 825-836. [http://dx.doi.org/10.1007/ s13311-015-0387-1]. [PMID: 26341731].
[264]
Martinotti, G.; Di Iorio, G.; Sepede, G.; De Berardis, D.; De Risio, L.; Di Giannantonio, M. Cannabis use and psychosis: theme introduction. Curr. Pharm. Des., 2012, 18(32), 4991-4998. [http://dx. doi.org/10.2174/138161212802884627]. [PMID: 22716149].
[265]
Rutrick, D.; Stein, D.J.; Subramanian, G.; Smith, B.; Fava, M.; Hasler, G.; Cha, J.H.; Gasparini, F.; Donchev, T.; Ocwieja, M.; Johns, D.; Gomez-Mancilla, B. Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: a proof-of-concept, randomized, placebo-controlled, phase 2 study. Adv. Ther., 2017, 34(2), 524-541. [http://dx.doi.org/10.1007/s12325-016-0468-5]. [PMID: 28044255].
[266]
Fux, M.; Benjamin, J.; Nemets, B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J. Psychiatr. Res., 2004, 38(3), 323-325. [http://dx.doi.org/10.1016/S0022-3956(03)00077-3]. [PMID: 15003438].
[267]
Sayyah, M.; Boostani, H.; Pakseresht, S.; Malayeri, A. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res., 2011, 189(3), 403-406. [http://dx.doi.org/ 10.1016/j.psychres.2011.01.019]. [PMID: 21329988].
[268]
Arabzadeh, S.; Shahhossenie, M.; Mesgarpour, B.; Rezaei, F.; Shalbafan, M.R.; Ghiasi, Z.; Akhondzadeh, S. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. Hum. Psychopharmacol., 2017, 32(4) [http://dx.doi.org/10.1002/hup.2584]. [PMID: 28485008].
[269]
Fux, M.; Levine, J.; Aviv, A.; Belmaker, R.H. Inositol treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 1996, 153(9), 1219-1221. [http://dx.doi.org/10.1176/ajp.153.9.1219]. [PMID: 8780431].
[270]
Askari, N.; Moin, M.; Sanati, M.; Tajdini, M.; Hosseini, S.M.; Modabbernia, A.; Najand, B.; Salimi, S.; Tabrizi, M.; Ashrafi, M.; Hajiaghaee, R.; Akhondzadeh, S. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs, 2012, 26(10), 883-892. [http://dx.doi.org/10.2165/11635850-000000000-00000]. [PMID: 22873680].
[271]
Dannon, P.N.; Sasson, Y.; Hirschmann, S.; Iancu, I.; Grunhaus, L.J.; Zohar, J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur. Neuropsychopharmacol., 2000, 10(3), 165-169. [http://dx.doi. org/10.1016/S0924-977X(00)00065-1]. [PMID: 10793318].
[272]
Ghaleiha, A.; Entezari, N.; Modabbernia, A.; Najand, B.; Askari, N.; Tabrizi, M.; Ashrafi, M.; Hajiaghaee, R.; Akhondzadeh, S. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J. Psychiatr. Res., 2013, 47(2), 175-180. [http://dx.doi.org/10.1016/j. jpsychires.2012.09.015]. [PMID: 23063327].
[273]
Haghighi, M.; Jahangard, L.; Mohammad-Beigi, H.; Bajoghli, H.; Hafezian, H.; Rahimi, A.; Afshar, H.; Holsboer-Trachsler, E.; Brand, S. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology (Berl.), 2013, 228(4), 633-640. [http://dx.doi. org/10.1007/s00213-013-3067-z]. [PMID: 23525525].
[274]
Modarresi, A.; Sayyah, M.; Razooghi, S.; Eslami, K.; Javadi, M.; Kouti, L. Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial. Pharmacopsychiatry, 2018, 51(6), 263-269. Epub ahead of print [http://dx.doi.org/10.1055/s-0043-120268]. [PMID: 29100251].
[275]
Sarris, J.; Oliver, G.; Camfield, D.A.; Dean, O.M.; Dowling, N.; Smith, D.J.; Murphy, J.; Menon, R.; Berk, M.; Blair-West, S.; Ng, C.H. Menon.; R.; Berk, M.; Blair-West, S.; Ng, C.H. N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study. CNS Drugs, 2015, 29(9), 801-809. [http://dx.doi.org/10.1007/s40263-015-0272-9]. [PMID: 26374743].
[276]
Afshar, H.; Roohafza, H.; Mohammad-Beigi, H.; Haghighi, M.; Jahangard, L.; Shokouh, P.; Sadeghi, M.; Hafezian, H. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol., 2012, 32(6), 797-803. [http://dx.doi.org/ 10.1097/JCP.0b013e318272677d]. [PMID: 23131885].
[277]
Paydary, K.; Akamaloo, A.; Ahmadipour, A.; Pishgar, F.; Emamzadehfard, S.; Akhondzadeh, S. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J. Clin. Pharm. Ther., 2016, 41(2), 214-219. [http://dx.doi.org/10.1111/jcpt.12370]. [PMID: 26931055].
[278]
Costa, D.L.C.; Diniz, J.B.; Requena, G.; Joaquim, M.A.; Pittenger, C.; Bloch, M.H.; Miguel, E.C.; Shavitt, R.G. Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry, 2017, 78(7), e766-e773. [http://dx.doi.org/10.4088/JCP. 16m11101]. [PMID: 28617566].
[279]
Grady, T.A.; Pigott, T.A.; L’Heureux, F.; Hill, J.L.; Bernstein, S.E.; Murphy, D.L. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am. J. Psychiatry, 1993, 150(5), 819-821. [http://dx.doi.org/10.1176/ ajp.150.5.819]. [PMID: 8480832].
[280]
McDougle, C.J.; Goodman, W.K.; Leckman, J.F.; Holzer, J.C.; Barr, L.C.; McCance-Katz, E.; Heninger, G.R.; Price, L.H. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am. J. Psychiatry, 1993, 150(4), 647-649. [http://dx.doi.org/10.1176/ajp.150.4.647]. [PMID: 8465885].
[281]
Hollander, E.; Kaplan, A.; Stahl, S.M. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J. Biol. Psychiatry, 2003, 4(1), 30-34. [http://dx.doi.org/10. 3109/15622970309167908]. [PMID: 12582975].
[282]
Greenberg, W.M.; Benedict, M.M.; Doerfer, J.; Perrin, M.; Panek, L.; Cleveland, W.L.; Javitt, D.C. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J. Psychiatr. Res., 2009, 43(6), 664-670. [http://dx.doi.org/10.1016/j.jpsychires. 2008.10.007]. [PMID: 19046587].
[283]
McDougle, C.J.; Price, L.H.; Goodman, W.K.; Charney, D.S.; Heninger, G.R. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J. Clin. Psychopharmacol., 1991, 11(3), 175-184. [http://dx. doi.org/10.1097/00004714-199106000-00005]. [PMID: 1820757].
[284]
Amiaz, R.; Fostick, L.; Gershon, A.; Zohar, J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur. Neuropsychopharmacol., 2008, 18(6), 455-461. [http://dx. doi.org/10.1016/j.euroneuro.2008.01.006]. [PMID: 18353618].
[285]
Pittenger, C.; Bloch, M.H.; Wasylink, S.; Billingslea, E.; Simpson, R.; Jakubovski, E.; Kelmendi, B.; Sanacora, G.; Coric, V. Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J. Clin. Psychiatry, 2015, 76(8), 1075-1084. [http://dx.doi.org/10.4088/JCP.14m09123]. [PMID: 26214725].
[286]
Besiroglu, L.; Agargun, M.Y.; Ozbebit, O.; Aydin, A. A discrimination based on autogenous versus reactive obsessions in obsessive-compulsive disorder and related clinical manifestations. CNS Spectr., 2006, 11(3), 179-186. [http://dx.doi.org/10.1017/ S1092852900014292]. [PMID: 16575374].
[287]
Lee, H.J.; Kwon, S.M. Two different types of obsession: autogenous obsessions and reactive obsessions. Behav. Res. Ther., 2003, 41(1), 11-29. [http://dx.doi.org/10.1016/S0005-7967(01)00101-2]. [PMID: 12488117].
[288]
Lee, H.J.; Telch, M.J. Autogenous/reactive obsessions and their relationship with OCD symptoms and schizotypal personality features. J. Anxiety Disord., 2005, 19(7), 793-805. [http://dx.doi.org/ 10.1016/j.janxdis.2004.10.001]. [PMID: 16076425].
[289]
Besiroglu, L.; Sozen, M.; Ozbebit, O.; Avcu, S.; Selvi, Y.; Bora, A.; Atli, A.; Unal, O.; Bulut, M.D. The involvement of distinct neural systems in patients with obsessive-compulsive disorder with autogenous and reactive obsessions. Acta Psychiatr. Scand., 2011, 124(2), 141-151. [http://dx.doi.org/10.1111/j.1600-0447.2011. 01726.x]. [PMID: 21627621].
[290]
Subirà, M.; Alonso, P.; Segalàs, C.; Real, E.; López-Solà, C.; Pujol, J.; Martínez-Zalacaín, I.; Harrison, B.J.; Menchón, J.M.; Cardoner, N.; Soriano-Mas, C. Brain structural alterations in obsessive-compulsive disorder patients with autogenous and reactive obsessions. PLoS One, 2013, 8(9)e75273 [http://dx.doi.org/10.1371/ journal.pone.0075273]. [PMID: 24098688].
[291]
Rufer, M.; Fricke, S.; Moritz, S.; Kloss, M.; Hand, I. Symptom dimensions in obsessive-compulsive disorder: prediction of cognitive-behavior therapy outcome. Acta Psychiatr. Scand., 2006, 113(5), 440-446. [http://dx.doi.org/10.1111/j.1600-0447.2005.0 0682.x]. [PMID: 16603035].
[292]
Shetti, C.N.; Reddy, Y.C.; Kandavel, T.; Kashyap, K.; Singisetti, S.; Hiremath, A.S.; Siddequehusen, M.U.; Raghunandanan, S. Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J. Clin. Psychiatry, 2005, 66(12), 1517-1523. [http:// dx.doi.org/10.4088/JCP.v66n1204]. [PMID: 16401151].
[293]
Denys, D.; Burger, H.; van Megen, H.; de Geus, F.; Westenberg, H. A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 2003, 18(6), 315-322. [http://dx.doi.org/10.1097/00004850-200311000-00002]. [PMID: 14571151].
[294]
Rosario-Campos, M.C.; Leckman, J.F.; Mercadante, M.T.; Shavitt, R.G.; Prado, H.S.; Sada, P.; Zamignani, D.; Miguel, E.C. Adults with early-onset obsessive-compulsive disorder. Am. J. Psychiatry, 2001, 158(11), 1899-1903. [http://dx.doi.org/10.1176/appi.ajp.158. 11.1899]. [PMID: 11691698].
[295]
Moritz, S.; Fricke, S.; Jacobsen, D.; Kloss, M.; Wein, C.; Rufer, M.; Katenkamp, B.; Farhumand, R.; Hand, I. Positive schizotypal symptoms predict treatment outcome in obsessive-compulsive disorder. Behav. Res. Ther., 2004, 42(2), 217-227. [http://dx.doi.org/ 10.1016/S0005-7967(03)00120-7]. [PMID: 14975782].
[296]
Overbeek, T.; Schruers, K.; Vermetten, E.; Griez, E. Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect. J. Clin. Psychiatry, 2002, 63(12), 1106-1112. [http://dx.doi.org/10.4088/JCP.v63n1204]. [PMID: 12523869].
[297]
Brakoulias, V.; Starcevic, V.; Belloch, A.; Dell’Osso, L.; Ferrão, Y.A.; Fontenelle, L.F.; Lochner, C.; Marazziti, D.; Martin, A.; Matsunaga, H.; Miguel, E.C.; Reddy, Y.C.; do Rosário, M.C.; Shavitt, R.G.; Sundar, A.S.; Stein, D.J.; Viswasam, K. International prescribing practices in obsessive-compulsive disorder (OCD). Hum. Psychopharmacol., 2016, 31(4), 319-324. [http://dx.doi.org/10. 1002/hup.2541]. [PMID: 27271200].
[298]
Stewart, S.E.; Jenike, E.A.; Hezel, D.M.; Stack, D.E.; Dodman, N.H.; Shuster, L.; Jenike, M.A. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J. Clin. Psychopharmacol., 2010, 30(1), 34-39. [http://dx.doi.org/10.1097/ JCP.0b013e3181c856de]. [PMID: 20075645].
[299]
Rodriguez, C.I.; Kegeles, L.S.; Levinson, A.; Feng, T.; Marcus, S.M.; Vermes, D.; Flood, P.; Simpson, H.B. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology, 2013, 38(12), 2475-2483. [http://dx.doi.org/10.1038/npp.2013.150]. [PMID: 23783065].
[300]
Hicks, J.K.; Swen, J.J.; Thorn, C.F.; Sangkuhl, K.; Kharasch, E.D.; Ellingrod, V.L.; Skaar, T.C.; Müller, D.J.; Gaedigk, A.; Stingl, J.C. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther., 2013, 93(5), 402-408. [http:// dx.doi.org/10.1038/clpt.2013.2]. [PMID: 23486447].
[301]
Müller, D.J.; Brandl, E.J.; Hwang, R.; Tiwari, A.K.; Sturgess, J.E.; Zai, C.C.; Lieberman, J.A.; Kennedy, J.L.; Richter, M.A. The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genet. Test. Mol. Biomarkers, 2012, 16(8), 897-903. [http://dx.doi.org/10.1089/gtmb. 2011.0327]. [PMID: 22775532].
[302]
Brandl, E.J.; Tiwari, A.K.; Zhou, X.; Deluce, J.; Kennedy, J.L.; Müller, D.J.; Richter, M.A. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J., 2014, 14(2), 176-181. [http:// dx.doi.org/10.1038/tpj.2013.12]. [PMID: 23545896].
[303]
Zai, G.; Brandl, E.J.; Müller, D.J.; Richter, M.A.; Kennedy, J.L. Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. Pharmacogenomics, 2014, 15(8), 1147-1157. [http://dx.doi.org/ 10.2217/pgs.14.83]. [PMID: 25084207].
[304]
Ramamoorthy, S.; Bauman, A.L.; Moore, K.R.; Han, H.; Yang-Feng, T.; Chang, A.S.; Ganapathy, V.; Blakely, R.D. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl. Acad. Sci. USA, 1993, 90(6), 2542-2546. [http://dx.doi.org/10. 1073/pnas.90.6.2542]. [PMID: 7681602].
[305]
Heils, A.; Teufel, A.; Petri, S.; Stöber, G.; Riederer, P.; Bengel, D.; Lesch, K.P. Allelic variation of human serotonin transporter gene expression. J. Neurochem., 1996, 66(6), 2621-2624. [http://dx. doi.org/10.1046/j.1471-4159.1996.66062621.x]. [PMID: 8632190].
[306]
Bloch, M.H.; Landeros-Weisenberger, A.; Sen, S.; Dombrowski, P.; Kelmendi, B.; Coric, V.; Pittenger, C.; Leckman, J.F. Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2008, 147B(6), 850-858. [http://dx.doi.org/ 10.1002/ajmg.b.30699]. [PMID: 18186076].
[307]
Zitterl, W.; Stompe, T.; Aigner, M.; Zitterl-Eglseer, K.; Ritter, K.; Zettinig, G.; Hornik, K.; Asenbaum, S.; Pirker, W.; Thau, K. Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers. Biol. Psychiatry, 2009, 66(12), 1115-1122. [http://dx.doi.org/10.1016/j.biopsych.2009.07.009]. [PMID: 19717141].
[308]
Corregiari, F.M.; Bernik, M.; Cordeiro, Q.; Vallada, H. Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder. Clinics (São Paulo), 2012, 67(4), 335-340. [http://dx.doi.org/10.6061/clinics/2012(04)06]. [PMID: 22522758].
[309]
Vulink, N.C.; Westenberg, H.G.; van Nieuwerburgh, F.; Deforce, D.; Fluitman, S.B.; Meinardi, J.S.; Denys, D. Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder. Int. J. Psychiatry Clin. Pract., 2012, 16(4), 277-283. [http://dx.doi.org/10.3109/ 13651501.2011.653375]. [PMID: 22414277].
[310]
Kariuki-Nyuthe, C.; Gomez-Mancilla, B.; Stein, D.J. Obsessive compulsive disorder and the glutamatergic system. Curr. Opin. Psychiatry, 2014, 27(1), 32-37. [http://dx.doi.org/10.1097/YCO. 0000000000000017]. [PMID: 24270485].
[311]
Milad, M.R.; Rauch, S.L. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn. Sci. (Regul. Ed.), 2012, 16(1), 43-51. [http://dx.doi.org/10.1016/j.tics.2011.11. 003] [PMID: 22138231].
[312]
Wendland, J.R.; Moya, P.R.; Timpano, K.R.; Anavitarte, A.P.; Kruse, M.R.; Wheaton, M.G.; Ren-Patterson, R.F.; Murphy, D.L. A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. Arch. Gen. Psychiatry, 2009, 66(4), 408-416. [http://dx.doi.org/10. 1001/archgenpsychiatry.2009.6]. [PMID: 19349310].
[313]
Rosenberg, D.R.; Keshavan, M.S.A.E.A.E. Bennett Research Award. Toward a neurodevelopmental model of of obsessive--compulsive disorder. Biol. Psychiatry, 1998, 43(9), 623-640. [http:// dx.doi.org/10.1016/S0006-3223(97)00443-5]. [PMID: 9582996].
[314]
Huyser, C.; Veltman, D.J.; de Haan, E.; Boer, F. Paediatric obsessive-compulsive disorder, a neurodevelopmental disorder? Evidence from neuroimaging. Neurosci. Biobehav. Rev., 2009, 33(6), 818-830. [http://dx.doi.org/10.1016/j.neubiorev.2009.01.003]. [PMID: 19428494].
[315]
Gassó, P.; Ortiz, A.E.; Mas, S.; Morer, A.; Calvo, A.; Bargalló, N.; Lafuente, A.; Lázaro, L. Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment pathways and white matter microstructure in child and adolescent patients with obsessive-compulsive disorder. J. Affect. Disord., 2015, 186, 284-292. [http://dx.doi.org/10.1016/j.jad.2015.07.035]. [PMID: 26254621].
[316]
Cappi, C.; Brentani, H.; Lima, L.; Sanders, S.J.; Zai, G.; Diniz, B.J.; Reis, V.N.; Hounie, A.G.; Conceição do Rosário, M.; Mariani, D.; Requena, G.L.; Puga, R.; Souza-Duran, F.L.; Shavitt, R.G.; Pauls, D.L.; Miguel, E.C.; Fernandez, T.V. Whole-exome sequencing in obsessive-compulsive disorder identifies rare mutations in immunological and neurodevelopmental pathways. Transl. Psychiatry, 2016, 6e764 [http://dx.doi.org/10.1038/tp.2016.30]. [PMID: 27023170].
[317]
Melo-Felippe, F.B.; de Salles Andrade, J.B.; Giori, I.G.; Vieira-Fonseca, T.; Fontenelle, L.F.; Kohlrausch, F.B. Catechol-O-methyltransferase gene polymorphisms in specific obsessive-compulsive disorder patients’ subgroups. J. Mol. Neurosci., 2016, 58(1), 129-136. [http://dx.doi.org/10.1007/s12031-015-0697-0]. [PMID: 26687156].
[318]
Qin, H.; Samuels, J.F.; Wang, Y.; Zhu, Y.; Grados, M.A.; Riddle, M.A.; Greenberg, B.D.; Knowles, J.A.; Fyer, A.J.; McCracken, J.T.; Murphy, D.L.; Rasmussen, S.A.; Cullen, B.A.; Piacentini, J.; Geller, D.; Stewart, S.E.; Pauls, D.; Bienvenu, O.J.; Goes, F.S.; Maher, B.; Pulver, A.E.; Valle, D.; Lange, C.; Mattheisen, M.; McLaughlin, N.C.; Liang, K.Y.; Nurmi, E.L.; Askland, K.D.; Nestadt, G.; Shugart, Y.Y. Whole-genome association analysis of treatment response in obsessive-compulsive disorder. Mol. Psychiatry, 2016, 21(2), 270-276. [http://dx.doi.org/10.1038/mp.2015. 32]. [PMID: 25824302].
[319]
Etheridge, L.A.; Crawford, T.Q.; Zhang, S.; Roelink, H. Evidence for a role of vertebrate Disp1 in long-range Shh signaling. Development, 2010, 137(1), 133-140. [http://dx.doi.org/10.1242/dev. 043547]. [PMID: 20023168].
[320]
Lister, J.F. Pharmacogenomics: A focus on antidepressants and atypical antipsychotics. Ment Health Clin, 2016, 6(1), 48-53. [http://dx.doi.org/10.9740/mhc.2016.01.048]. [PMID: 29955447].
[321]
Fagerness, J.; Fonseca, E.; Hess, G.P.; Scott, R.; Gardner, K.R.; Koffler, M.; Fava, M.; Perlis, R.; Brennan, F.X.; Lombard, J. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am. J. Manag. Care, 2014, 20(5), e146-e156. [PMID: 25326929].
[322]
Singh, A.B. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin. Psychopharmacol. Neurosci., 2015, 13(2), 150-156. [http://dx.doi.org/10.9758/cpn.2015.13.2.150]. [PMID: 26243841].
[323]
Russell, E.J.; Fawcett, J.M.; Mazmanian, D. Risk of obsessive-compulsive disorder in pregnant and postpartum women: a meta-analysis. J. Clin. Psychiatry, 2013, 74(4), 377-385. [http://dx.doi. org/10.4088/JCP.12r07917]. [PMID: 23656845].
[324]
Labad, J.; Menchón, J.M.; Alonso, P.; Segalàs, C.; Jiménez, S.; Vallejo, J. Female reproductive cycle and obsessive-compulsive disorder. J. Clin. Psychiatry, 2005, 66(4), 428-435. [http://dx.doi. org/10.4088/JCP.v66n0404]. [PMID: 15816784].
[325]
Uguz, F.; Gezginc, K.; Zeytinci, I.E.; Karatayli, S.; Askin, R.; Guler, O.; Kir, S.F.; Emul, H.M.; Ozbulut, O.; Gecici, O. Obsessive-compulsive disorder in pregnant women during the third trimester of pregnancy. Compr. Psychiatry, 2007, 48(5), 441-445. [http://dx.doi.org/10.1016/j.comppsych.2007.05.001]. [PMID: 17707252].
[326]
Forray, A.; Focseneanu, M.; Pittman, B.; McDougle, C.J.; Epperson, C.N. Onset and exacerbation of obsessive-compulsive disorder in pregnancy and the postpartum period. J. Clin. Psychiatry, 2010, 71(8), 1061-1068. [http://dx.doi.org/10.4088/JCP.09m05381blu]. [PMID: 20492843].
[327]
Loomans, E.M.; van der Stelt, O.; van Eijsden, M.; Gemke, R.J.; Vrijkotte, T.; den Bergh, B.R. Antenatal maternal anxiety is associated with problem behaviour at age five. Early Hum. Dev., 2011, 87(8), 565-570. [http://dx.doi.org/10.1016/j.earlhumdev.2011.04. 014]. [PMID: 21576004].
[328]
Sanchez, S.E.; Puente, G.C.; Atencio, G.; Qiu, C.; Yanez, D.; Gelaye, B.; Williams, M.A. Risk of spontaneous preterm birth in relation to maternal depressive, anxiety, and stress symptoms. J. Reprod. Med., 2013, 58(1-2), 25-33. [PMID: 23447915].
[329]
Van Batenburg-Eddes, T.; Brion, M.J.; Henrichs, J.; Jaddoe, V.W.; Hofman, A.; Verhulst, F.C.; Lawlor, D.A.; Davey Smith, G.; Tiemeier, H. Parental depressive and anxiety symptoms during pregnancy and attention problems in children: a cross-cohort consistency study. J. Child Psychol. Psychiatry, 2013, 54(5), 591-600. [http://dx.doi.org/10.1111/jcpp.12023]. [PMID: 23215861].
[330]
Leis, J.A.; Heron, J.; Stuart, E.A.; Mendelson, T. Associations between maternal mental health and child emotional and behavioral problems: does prenatal mental health matter? J. Abnorm. Child Psychol., 2014, 42(1), 161-171. [http://dx.doi.org/10.1007/s10802-013-9766-4]. [PMID: 23748337].
[331]
Ding, X.X.; Wu, Y.L.; Xu, S.J.; Zhu, R.P.; Jia, X.M.; Zhang, S.F.; Huang, K.; Zhu, P.; Hao, J.H.; Tao, F.B. Maternal anxiety during pregnancy and adverse birth outcomes: a systematic review and meta-analysis of prospective cohort studies. J. Affect. Disord., 2014, 159, 103-110. [http://dx.doi.org/10.1016/j.jad.2014.02.027]. [PMID: 24679397].
[332]
Uguz, F.; Onder Sonmez, E.; Sahingoz, M.; Gokmen, Z.; Basaran, M.; Gezginc, K.; Sonmez, G.; Kaya, N.; Yilmaz, E.; Erdem, S.S.; Dulger, H.H.; Cicekler, H.; Tasyurek, E. Neuroinflammation in the fetus exposed to maternal obsessive-compulsive disorder during pregnancy: a comparative study on cord blood tumor necrosis factor-alpha levels. Compr. Psychiatry, 2014, 55(4), 861-865. [http:// dx.doi.org/10.1016/j.comppsych.2013.12.018]. [PMID: 24480417].
[333]
Byatt, N.; Deligiannidis, K.M.; Freeman, M.P. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr. Scand., 2013, 127(2), 94-114. [http://dx.doi.org/10. 1111/acps.12042]. [PMID: 23240634].
[334]
Yonkers, K.A.; Wisner, K.L.; Stewart, D.E.; Oberlander, T.F.; Dell, D.L.; Stotland, N.; Ramin, S.; Chaudron, L.; Lockwood, C. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen. Hosp. Psychiatry, 2009, 31(5), 403-413. [http://dx.doi.org/10.1016/j.genhosppsych.2009.04. 003]. [PMID: 19703633].
[335]
Uguz, F. Pharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approach. Rev. Bras. Psiquiatr., 2015, 37(4), 334-342. [http://dx.doi.org/10.1590/1516-4446-2015-1673]. [PMID: 26692431].
[336]
Kellner, M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin. Neurosci., 2010, 12(2), 187-197. [PMID: 20623923].
[337]
Ellfolk, M.; Malm, H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod. Toxicol., 2010, 30(2), 249-260. [http://dx.doi.org/10.1016/ j.reprotox.2010.04.015]. [PMID: 20447455].
[338]
Gentile, S. Drug treatment for mood disorders in pregnancy. Curr. Opin. Psychiatry, 2011, 24(1), 34-40. [http://dx.doi.org/10.1097/ YCO.0b013e3283413451]. [PMID: 21088587].
[339]
Malm, H.; Artama, M.; Gissler, M.; Ritvanen, A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet. Gynecol., 2011, 118(1), 111-120. [http://dx.doi.org/10. 1097/AOG.0b013e318220edcc]. [PMID: 21646927].
[340]
Lorenzo, L.; Byers, B.; Einarson, A. Antidepressant use in pregnancy. Expert Opin. Drug Saf., 2011, 10(6), 883-889. [http://dx. doi.org/10.1517/14740338.2011.583917]. [PMID: 21545242].
[341]
Myles, N.; Newall, H.; Ward, H.; Large, M. Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations. Aust. N. Z. J. Psychiatry, 2013, 47(11), 1002-1012. [http://dx.doi.org/10.1177/0004867413492219]. [PMID: 23761574].
[342]
Grigoriadis, S. VonderPorten, E.H.; Mamisashvili, L.; Roerecke, M.; Rehm, J.; Dennis, C.L.; Koren, G.; Steiner, M.; Mousmanis, P.; Cheung, A.; Ross, L.E. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J. Clin. Psychiatry, 2013, 74(4), e293-e308. [http://dx.doi.org/10.4088/JCP.12r07966]. [PMID: 23656855].
[343]
Klieger-Grossmann, C.; Weitzner, B.; Panchaud, A.; Pistelli, A.; Einarson, T.; Koren, G.; Einarson, A. Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study. J. Clin. Pharmacol., 2012, 52(5), 766-770. [http://dx.doi.org/10.1177/ 0091270011405524]. [PMID: 22075232].
[344]
Bellantuono, C.; Bozzi, F.; Orsolini, L.; Catena-Dell’Osso, M. The safety of escitalopram during pregnancy and breastfeeding: a comprehensive review. Hum. Psychopharmacol., 2012, 27(6), 534-539. [http://dx.doi.org/10.1002/hup.2265]. [PMID: 23044635].
[345]
Alwan, S.; Reefhuis, J.; Rasmussen, S.A.; Friedman, J.M. Patterns of antidepressant medication use among pregnant women in a United States population. J. Clin. Pharmacol., 2011, 51(2), 264-270. [http://dx.doi.org/10.1177/0091270010373928]. [PMID: 20663997].
[346]
Andrade, S.E.; Raebel, M.A.; Brown, J.; Lane, K.; Livingston, J.; Boudreau, D.; Rolnick, S.J.; Roblin, D.; Smith, D.H.; Willy, M.E.; Staffa, J.A.; Platt, R. Use of antidepressant medications during pregnancy: a multisite study. Am. J. Obstet. Gynecol., 2008, 198(2), 194.e1-194.e5. [http://dx.doi.org/10.1016/j.ajog.2007.07. 036]. [PMID: 17905176].
[347]
Yonkers, K.A.; Blackwell, K.A.; Glover, J.; Forray, A. Antidepressant use in pregnant and postpartum women. Annu. Rev. Clin. Psychol., 2014, 10, 369-392. [http://dx.doi.org/10.1146/annurev-clinpsy-032813-153626]. [PMID: 24313569].
[348]
Gentile, S. Tricyclic antidepressants in pregnancy and puerperium. Expert Opin. Drug Saf., 2014, 13(2), 207-225. [http://dx.doi.org/10. 1517/14740338.2014.869582]. [PMID: 24383525].
[349]
Källén, B.A.; Otterblad Olausson, P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod. Toxicol., 2003, 17(3), 255-261. [http://dx.doi.org/10.1016/S0890-6238(03)00012-1]. [PMID: 12759093].
[350]
Källén, B.; Otterblad Olausson, P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod. Toxicol., 2006, 21(3), 221-222. [http://dx.doi.org/10.1016/j.reprotox.2005. 11.006]. [PMID: 16406480].
[351]
Udechuku, A.; Nguyen, T.; Hill, R.; Szego, K. Antidepressants in pregnancy: a systematic review. Aust. N. Z. J. Psychiatry, 2010, 44(11), 978-996. [PMID: 21034181].
[352]
Seibell, P.J.; Hollander, E. Management of obsessive-compulsive disorder. F1000Prime Rep., 2014, 6, 68. [http://dx.doi.org/10. 12703/P6-68]. [PMID: 25165567].
[353]
Suri, R.; Altshuler, L.; Hellemann, G.; Burt, V.K.; Aquino, A.; Mintz, J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am. J. Psychiatry, 2007, 164(8), 1206-1213. [http://dx.doi.org/10.1176/ appi.ajp.2007.06071172]. [PMID: 17671283].
[354]
Andrade, C. Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: benefits and risks. J. Clin. Psychiatry, 2013, 74(12), e1128-e1133. [http://dx. doi.org/10.4088/JCP.13f08883]. [PMID: 24434100].
[355]
Diniz, J.B.; Shavitt, R.G.; Pereira, C.A.; Hounie, A.G.; Pimentel, I.; Koran, L.M.; Dainesi, S.M.; Miguel, E.C. Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. J. Psychopharmacol. (Oxford), 2010, 24(3), 297-307. [http://dx.doi.org/10.1177/0269881108099423]. [PMID: 19164490].
[356]
Skapinakis, P.; Papatheodorou, T.; Mavreas, V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur. Neuropsychopharmacol., 2007, 17(2), 79-93. [http://dx.doi.org/10.1016/j.euroneuro.2006.07.002]. [PMID: 16904298].
[357]
Bloch, M.H.; Peterson, B.S.; Scahill, L.; Otka, J.; Katsovich, L.; Zhang, H.; Leckman, J.F. Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome. Arch. Pediatr. Adolesc. Med., 2006, 160(1), 65-69. [http://dx. doi.org/10.1001/archpedi.160.1.65]. [PMID: 16389213].
[359]
Poppe, C.; Müller, S.T.; Greil, W.; Walder, A.; Grohmann, R.; Stübner, S. Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012. J. Affect. Disord., 2016, 200, 89-96. [http://dx.doi.org/10.1016/j.jad.2016.04.035]. [PMID: 27130958].
[360]
Bandelow, B.; Sher, L.; Bunevicius, R.; Hollander, E.; Kasper, S.; Zohar, J.; Möller, H.J. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract., 2012, 16(2), 77-84. [http://dx.doi.org/10.3109/13651501. 2012.667114]. [PMID: 22540422].
[361]
Koran, L.M.; Simpson, H.B. Guideline Watch (March 2013): Practice Guideline for the Treatment of patients with Obsessive-Compulsive Disorder; American Psychiatric Association: Arlington, VA, 2013.
[362]
Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg., 2010, 8(5), 336-341. [http://dx.doi.org/10. 1016/j.ijsu.2010.02.007]. [PMID: 20171303].
